[{"text": "RDY Q3 Earnings Match Estimates, Generics Revenues Rise Y/Y, Stock Down Zacks Equity Research Fri, Jan 24, 2025, 7:07 PM 4 min read In This Article: RDY Dr. Reddy's Laboratories Limited RDY reported third-quarter fiscal 2025 earnings of 20 cents per American Depositary Share (ADS), which matched the Zacks Consensus Estimate. The company reported earnings of 19 cents per ADS in the year-ago quarter. See the Zacks Earnings Calendar to stay ahead of market-making news. Revenues grew 16% year over year to $977 million, which surpassed the Zacks Consensus Estimate of $875 million. The year-over-year improvement was primarily driven by growth in global generics revenues. The stock likely declined 6.2% on Thursday due to the company\u2019s fiscal third-quarter results. RDY\u2019s Q3 Results in Detail Dr. Reddy\u2019s reported revenues under three segments \u2014 Global Generics, Pharmaceutical Services & Active Ingredients (PSAI) and Others. Global Generics revenues totaled INR 73.8 billion, up 17% year over year. The increase was primarily driven by revenues from the recently acquired Nicotine Replacement Therapy (NRT) portfolio, higher volumes and new product launches. Dr. Reddy\u2019s launched four new products in the United States during the reported quarter. As of Dec. 31, 2024, cumulatively, 79 generic filings were pending approval from the FDA (75 abbreviated new drug applications [ANDAs] and four new drug applications). Of these 75 ANDAs, 44 were Para IVs. Shares of Dr. Reddy\u2019s have lost 7.4% in the past three months against the\u00a0industry\u2019s 12.1% growth. Zacks Investment Research Image Source: Zacks Investment Research PSAI revenues amounted to INR 8.2 billion, up 5% from the year-ago level. The improvement was driven by momentum in base business volumes, revenues from new product launches and favorable forex, partially offset by adverse price variance. Revenues in the Others segment totaled INR 1.6 billion, up 33% year over year. Gross margin improved to 58.7% from 58.5% in the year-ago quarter due to a favorable product mix and overhead leverage. However, the uptick was partially offset by price erosion in generics markets. Research and development expenses jumped 20% year over year to $78 million, driven by ongoing development efforts across generics, biosimilars and novel oncology assets. Selling, general and administrative expenses totaled $282 million, up 19% year over year. The increase was largely due to costs associated with the NRT business, investments in business growth and other initiatives, along with higher freight costs. Key Pipeline Updates From RDY During the quarter, Dr. Reddy\u2019s signed a voluntary licensing agreement with Gilead Sciences GILD to manufacture and commercialize lenacapavir in India and other countries. Story Continues Gilead\u2019s lenacapavir is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection, failing their current antiretroviral regimen due to resistance, intolerance, or safety considerations. Additionally, GILD\u2019s lenacapavir is currently under investigation for the prevention of HIV (PrEP). Dr. Reddy\u2019s also reported encouraging initial data from the first eight patients in the phase I SWASTH study of ribrecabtagene autoleucel (DRL-1801) for relapsed / refractory multiple myeloma (MM) patients, marking this as India\u2019s first study for a novel autologous BCMA directed CAR-T cell therapy. Dr. Reddy\u2019s is currently preparing to begin phase II development of DRL-1801 for MM. Dr. Reddy's Laboratories Ltd Price and Consensus Dr. Reddy's Laboratories Ltd Price and Consensus Dr. Reddy's Laboratories Ltd price-consensus-chart | Dr. Reddy's Laboratories Ltd Quote Regulatory Updates In the third quarter of fiscal 2025, Dr. Reddy\u2019s partner, Alvotech, completed regulatory filing seeking approval for a generic version of Amgen\u2019s Prolia and Xgeva (denosumab). Dr. Reddy\u2019s has launched BixiBat (elobixibat) in India, a first-in-class drug for chronic constipation. The company is the first to launch elobixibat in India. The drug works by inhibiting bile acid reabsorption and enhancing colonic motility, fluid secretion and bowel movements. In November 2024, RDY launched a biosimilar of Coherus BioSciences \u2019 CHRS Loqtorzi (toripalimab) in India under the brand name Zytorvi for the treatment of adults with recurrent or metastatic nasopharyngeal carcinoma, a rare form of head and neck cancer. Loqtorzi, a novel anti-PD-1 monoclonal antibody, is a new biological entity that has been developed by Coherus in collaboration with China-based Junshi Biosciences. RDY\u2019s Zacks Rank & Stock to Consider Dr. Reddy\u2019s currently carries a Zacks Rank #3 (Hold). A better-ranked stock from the sector is Alnylam Pharmaceuticals ALNY, carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here . In the past 30 days, estimates for Alnylam Pharmaceuticals\u2019 2024 loss per share have remained constant at 39 cents. The estimate for 2025 earnings per share is currently pegged at 40 cents. In the past three months, shares of Alnylam Pharmaceuticals have lost 3.3%. ALNY\u2019s earnings beat estimates in three of the trailing four quarters and matched once, delivering an average surprise of 65.67%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Dr. Reddy's Laboratories Ltd (RDY) : Free Stock Analysis Report Alnylam Pharmaceuticals, Inc. (ALNY) : Free Stock Analysis Report Gilead Sciences, Inc. (GILD) : Free Stock Analysis Report Coherus BioSciences, Inc. (CHRS) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CHRS", "date": "2025-01-24T19:07:00", "sentiment": {"score": 0.8501076549291611, "confidence": 0.9151543974876404, "probabilities": {"positive": 0.9151543974876404, "negative": 0.06504674255847931, "neutral": 0.019798820838332176}}, "embedding": [-0.15733647346496582, -0.056682318449020386, -0.09750157594680786, -0.036263447254896164, -0.03133941441774368, 0.03416941687464714, -0.017087381333112717, 0.2467089593410492, 0.05556786060333252, 0.1005789190530777, -0.06838324666023254, 0.23984622955322266, 0.033564213663339615, 0.06662119925022125, 0.02609100192785263, 0.009434249252080917, 0.058449745178222656, -0.042201876640319824, -0.12231289595365524, 0.028609400615096092, 0.01573825813829899, 0.11930689960718155, 0.11551222205162048, 0.034020889550447464, 0.05970616266131401, -0.018533114343881607, -0.1665147840976715, -0.06293956190347672, -0.03190351277589798, -0.019315900281071663, -0.04155177250504494, 0.16898882389068604, 0.04785838723182678, -0.06069076061248779, 0.016309471800923347, -0.12479834258556366, -0.11225125193595886, 0.12070610374212265, 0.13843832910060883, 0.03104519471526146, -0.0029494836926460266, 0.02652285434305668, -0.23514150083065033, -0.003366595134139061, -0.07169106602668762, -0.18397116661071777, -0.01565263420343399, 0.09358039498329163, 0.06975410133600235, 0.06129680201411247, -0.13739868998527527, -0.09942077100276947, 0.09735234081745148, 0.007535917218774557, -0.11060015857219696, -0.12324816733598709, -0.039931222796440125, -0.05973493307828903, -0.020364297553896904, 0.03328578919172287, -0.004009835422039032, -0.05818318575620651, -0.028177298605442047, -0.02448808029294014, 0.0845755934715271, 0.017576711252331734, -0.017968524247407913, -0.019604114815592766, 0.008146691136062145, -0.06366248428821564, 0.019878840073943138, -0.00836899969726801, -0.05601239949464798, 0.07595331966876984, -0.09421174973249435, 0.08525535464286804, 0.14841870963573456, 0.20204804837703705, 0.03190720081329346, -0.10141988098621368, 0.047665610909461975, -0.05230853334069252, -0.0046478514559566975, 0.0493580624461174, 0.03901125490665436, 0.04365105181932449, 0.06358754634857178, 0.13304981589317322, 0.07287535071372986, 0.040544863790273666, 0.1012047529220581, 0.024937698617577553, 0.061913326382637024, -0.00873442180454731, -0.07115905731916428, -0.07105143368244171, -0.038336146622896194, -0.007330911699682474, 0.07874266058206558, 0.10381050407886505, 0.07228924334049225, 0.04621656611561775, -0.07646577060222626, -0.04068027809262276, -0.012148633599281311, -0.039860449731349945, 0.04780954867601395, -0.0069837383925914764, -0.042396463453769684, 0.04522281140089035, -0.1355835497379303, 0.07749362289905548, -0.08894722163677216, -0.0008176025003194809, -0.16374075412750244, 0.06265459954738617, 0.010989570990204811, 0.0875258520245552, 0.10462833940982819, 0.022123126313090324, 0.09927166253328323, 0.1428423523902893, 0.010912037454545498, -0.07651220262050629, -0.0398380346596241, 0.10900067538022995, -0.0955602377653122, 1.1573172408651409e-32, -0.055613234639167786, 0.14026008546352386, -0.013933619484305382, -0.052088432013988495, -0.00529626477509737, 0.08318642526865005, 0.011580772697925568, -0.008858857676386833, 0.04959958791732788, -0.16691109538078308, -0.20820102095603943, 0.05247184634208679, -0.030070267617702484, -0.011873237788677216, -0.06123005971312523, -0.08207503706216812, -0.10637331008911133, 0.00394158810377121, 0.021608982235193253, -0.0142868896946311, 0.019432449713349342, -0.05859321355819702, -0.009975915774703026, 0.17659340798854828, -0.06927847862243652, 0.06537064909934998, -0.11581328511238098, 0.0885603129863739, -0.08748519420623779, 0.054722778499126434, -0.021904252469539642, -0.011855358257889748, 0.010677824728190899, -0.1411762833595276, -0.04773607850074768, -0.04637850075960159, 0.014456063508987427, -0.08681110292673111, 0.12611892819404602, 0.07275755703449249, 0.03524375334382057, 0.10181495547294617, -0.1038457602262497, -0.044967930763959885, -0.065895676612854, 0.05153180658817291, -0.10165581852197647, 0.17888201773166656, -0.03984127566218376, -0.001497805118560791, -0.1555706262588501, -0.02279813587665558, -0.04544182866811752, -0.022418875247240067, -0.04553438723087311, -0.04976770281791687, -0.023525286465883255, -0.1489454209804535, 0.09275422990322113, 0.11395405232906342, 0.03495534881949425, 0.06794412434101105, 0.07012030482292175, 0.039753787219524384, -0.18278245627880096, 0.11553117632865906, 0.03707839548587799, -0.008560296148061752, -0.028750505298376083, 0.1768537163734436, 0.04259529337286949, -0.003963110037147999, 0.16803684830665588, 0.022120147943496704, 0.20423179864883423, -0.17876005172729492, 0.015823805704712868, 0.0670064240694046, 0.035010866820812225, 0.11654680967330933, 0.057295046746730804, -0.011755877174437046, -0.0370672233402729, 0.0418839268386364, -0.004962088540196419, -0.13453757762908936, 0.04294922947883606, -0.016093313694000244, 0.03406570851802826, -0.017676113173365593, -0.044075287878513336, -0.08643247187137604, -0.1230093464255333, 0.07088380306959152, 0.026474859565496445, -1.0504556942941761e-32, -0.11973217129707336, 0.18198135495185852, 0.07046539336442947, -0.037363793700933456, -0.07018664479255676, -0.061637185513973236, 0.009710938669741154, 0.11825060844421387, 0.0654120147228241, -0.06122802942991257, 0.07044003903865814, 0.04276697710156441, -0.06470097601413727, 0.0625385046005249, -0.10278043150901794, 0.10714630782604218, 0.008452849462628365, -0.15803465247154236, -0.008184554986655712, -0.03237485885620117, 0.04556020721793175, 0.11240214854478836, -0.0670185312628746, 0.16421504318714142, 0.08368419855833054, 0.07099615782499313, 0.0047394027933478355, 0.1305101215839386, 0.07867942750453949, 0.02551036886870861, 0.022055067121982574, -0.006713252514600754, -0.19859114289283752, 0.05179266631603241, 0.02395699732005596, 0.023621808737516403, 0.0732048898935318, -0.12299331277608871, -0.011606628075242043, -0.11210010945796967, 0.15341216325759888, -0.010390602052211761, -0.008998433127999306, 0.10625140368938446, -0.0008409610018134117, -0.05030593276023865, -0.021940987557172775, -0.001366943120956421, 0.15459375083446503, -0.009925602003932, 0.018420400097966194, 0.07210496813058853, -0.016393736004829407, 0.13182446360588074, -0.12166199088096619, -0.06206492707133293, 0.10243638604879379, 0.003577862400561571, -0.14820723235607147, -0.0034708380699157715, 0.060271166265010834, 0.06812766194343567, -0.12758852541446686, -0.021366912871599197, -0.023579422384500504, -0.10550640523433685, 0.1145453006029129, -0.04404325783252716, 0.14150677621364594, -0.1757904589176178, -0.005444019101560116, -0.09196140617132187, 0.09056247770786285, -0.196348175406456, -0.10708914697170258, 0.1784239411354065, -0.08042523264884949, -0.10894908010959625, -0.12061542272567749, -0.051209867000579834, 0.027332264930009842, -0.04648025333881378, 0.04804631322622299, -0.027681976556777954, -0.05612815544009209, 0.1293698251247406, -0.026113519445061684, -0.016217267140746117, -0.16109445691108704, 0.10414862632751465, -0.06265787780284882, -0.1486903429031372, -0.16351407766342163, 0.14329367876052856, 0.10892806947231293, -1.0004268347074685e-07, 0.16962921619415283, -0.10171087086200714, 0.07824704051017761, 0.02525065839290619, 0.11601916700601578, -0.0357617512345314, -0.13688763976097107, 0.12260977923870087, 0.06967893242835999, 0.17375808954238892, 0.033048227429389954, 0.11532963812351227, -0.19147169589996338, 0.04402128607034683, -0.05891156196594238, 0.015505359508097172, -0.13819807767868042, 0.11948421597480774, -0.035811647772789, -0.05819473788142204, -0.07590311765670776, 0.09484700858592987, 0.05361836031079292, -0.16584384441375732, 0.09070153534412384, -0.090513676404953, -0.060696206986904144, -0.03394467011094093, 0.05784033238887787, -0.044167038053274155, 0.12913411855697632, -0.010888693854212761, 0.09631889313459396, -0.015022434294223785, -0.08716725558042526, -0.18279246985912323, 0.06810285151004791, 0.0068416111171245575, 0.014105038717389107, -0.02003127709031105, -0.02628757804632187, -0.010846742428839207, -0.07085096091032028, 0.036340780556201935, -0.06250964105129242, -0.09410344064235687, -0.19902479648590088, -0.007808607537299395, 0.057024553418159485, -0.19969312846660614, 0.12075437605381012, -0.006605575326830149, 0.08836419880390167, -0.0660918653011322, -0.06318721175193787, 0.042643964290618896, -0.16770952939987183, -0.07115654647350311, -0.07191532850265503, -0.08760015666484833, 0.009231789037585258, -0.25239992141723633, 0.15539759397506714, 0.05083446949720383], "changes": {"1wk": -4.838714639304418}}, {"text": "Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025 Coherus BioSciences, Inc. Wed, Jan 22, 2025, 3:00 PM 11 min de lectura En este art\u00edculo: CHRS Coherus BioSciences, Inc. \u2013 Casdozokitug, in combination with atezolizumab/bevacizumab, final data demonstrate durability of response and improvement in depth of response including a 17.2% complete response rate \u2013 \u2013 Antitumor activity was observed across both viral and non-viral etiologies \u2013 \u2013 Data support continued evaluation of casdozokitug with VEGF and PD-(L)1 blockade in HCC \u2013 - Randomized Phase 2 trial evaluating casdozokitug/bevacizumab/toripalimab now open for enrollment \u2013 REDWOOD CITY, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc.\u00a0(Coherus, NASDAQ: CHRS), today announced final data from its Phase 2 open label clinical trial evaluating casdozokitug (casdozo), a selective and potent Interleukin (IL)-27-targeting antibody, in combination with atezolizumab (atezo) and bevacizumab (bev) in treatment na\u00efve patients with unresectable locally advanced or metastatic hepatocellular carcinoma (HCC). These data are being presented at the 2025 ASCO Gastrointestinal Cancers Symposium taking place January 23-25, 2025, in San Francisco, California. These data showed an overall response rate of 38% compared to initially announced 27% 1 , and complete responses (CR) per RECIST v1.1 increased to 17.2% compared to previously announced 10.3% 2 and initial assessment of 0% 1 , demonstrating both an increase in ORR and a deepening of responses compared to previous datasets.\u00a0Importantly, responses were seen in viral and nonviral disease, and toxicity was consistent with the known safety profiles of atezolizumab and bevacizumab, with no new safety signals identified. These data support continued evaluation of casdozo with other therapies, including a trial of casdozo/toripalimab (tori)/bev in HCC, which Coherus has now opened for enrollment. Casdozo is a first-in-class antibody, and the only clinical-stage immunomodulatory cytokine antagonist targeting IL-27, an immunoregulatory cytokine involved in suppressing anti-tumor immune responses and an important new target for cancer treatment. \u201cThe casdozo data in HCC demonstrate translation of the preclinical data in liver cancer to first-line HCC cancer patients with efficacy and a favorable safety profile. These data support the ongoing development of IL-27 as a promising novel target for advanced solid tumors,\u201d said Rosh Dias, M.D., Coherus\u2019 Chief Medical Officer. \u201cWe recently opened enrollment for our randomized, controlled, multinational Phase 2 trial of casdozo in combination with toripalimab, our anti-PD-1 antibody, plus bev. The combination of tori plus bev has demonstrated promising Phase 3 results in HCC 3 , and we believe the addition of casdozo may further enhance anti-tumor effects and advance our next-generation immuno-oncology combinations focused on overcoming immune suppression in the tumor microenvironment.\u201d La historia contin\u00faa \u201cThe treatment landscape for liver cancer, particularly for patients who are not eligible for surgery or who are metastatic, has improved in recent years thanks to immunotherapy combinations. However, there is still a clear unmet need for novel treatment options that can further improve survival without added toxicity,\u201d said Daneng Li, M.D., Associate Professor in the Department of Medical Oncology & Therapeutics Research and Co-Director, Liver Cancer Collaborative Program, City of Hope Comprehensive Cancer Center. \u201cThese final casdozo data continue to be encouraging and compare very favorably in the current treatment landscape, and speak to the potential for its novel anti-IL-27 mechanism to address these substantial unmet needs.\u201d Results from Phase 2 trial evaluating casdozo/atezo/bev combination in HCC This open-label Phase 2 clinical trial evaluated casdozo in combination with atezo and bev in 30 treatment-na\u00efve patients with unresectable locally advanced or metastatic HCC. Patients received casdozokitug 10 mg/kg IV q3w in combination with atezolizumab (1200 mg) and bevacizumab (15 mg/kg). The primary endpoint was safety and tolerability. Key secondary endpoints included PFS and ORR based on investigator review per RECIST v1.1 (primary) and mRECIST (secondary), as well as disease control rate (DCR). As of the data cutoff date of September 4, 2024: Triplet blockade of the IL-27, PD-(L)1 and VEGF inhibitors with casdozo/atezo/bev demonstrated an acceptable safety profile with promising antitumor activity in immunotherapy na\u00efve HCC. Triplet combination treatment was well tolerated with a side effect profile consistent with known adverse event (AE) profiles of atezo/bev. Encouraging early activity with casdozo/atezo/bev: RECIST v1.1: ORR of 38% (n=29) with 11 objective responses, including 5 complete responses and 6 confirmed partial responses; median progression-free survival (PFS) of 8.1 months and disease control rate of 58.6%. mRECIST: ORR of 43% (n=28) with 12 objective responses, including 5 complete responses and 7 confirmed partial responses; median PFS of 8.4 months and disease control rate of 60.7%. Biomarker data show peripheral inhibition of IL-27 signaling and immune activation in NK and T cells following treatment, consistent with the casdozo preclinical data and mechanism of action. These results support continued evaluation of casdozo with VEGF and PD-(L)1 blockade in HCC. Recent Launch of New Phase 2 trial evaluating casdozo in combination with bev and toripalimab Coherus has initiated a new randomized Phase 2 study ( NCT06679985 ) evaluating casdozo, in combination with bev and tori, Coherus\u2019 next-generation anti-PD-1 monoclonal antibody, in participants with unresectable locally advanced or metastatic HCC. This randomized, parallel, open-label Phase 2 study is designed to evaluate the safety, efficacy, and Project Optimus 4 dosing of the triplet combination. The study is expected to enroll up to 72 patients, who will be randomized to receive one of two biologically active doses of casdozo with tori plus bev or tori plus bev without casdozo. ASCO-GI 2025 Presentation Details Title: Results from a phase 2 study of triplet blockade of the IL-27, PD-(L)1, and VEGF pathways with casdozokitug (casdozo, CHS-388) in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (uHCC) Lead Author: Daneng Li, City of Hope National Comprehensive Cancer Center Abstract 605 : Poster Board #D6 Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract Date and Time: Friday, January 24, 2025; 11:30am \u2013 1:00pm PT About Hepatocellular Carcinoma Hepatobiliary cancers include a spectrum of invasive carcinomas arising in the liver (hepatocellular carcinoma; HCC), gall bladder, and bile ducts (collectively called biliary tract cancers). The most common type of primary liver cancer in adults is HCC (accounting for ~90%), which is the third leading cause of cancer-related deaths worldwide. According to the NCI Surveillance, Epidemiology and End Results Program (SEER), there will be an estimated 41,630 new cases and 29,840 deaths from liver and intrahepatic bile duct cancer in the US in 2024. 5 The U.S. 5-year relative survival rate for liver and intrahepatic bile duct cancer is 21.7%. 5 The liver cancer treatment pattern has changed in recent years with the emergence of immunotherapy combinations and will continue to evolve as more treatment options become available for these highly lethal cancers. About Casdozokitug Casdozokitug is a first-in-class human anti-IL-27 antibody designed to inhibit the activity of this immunosuppressive cytokine. Particular tumor types have been identified where IL-27 appears to play an important role in the immunosuppressive tumor microenvironment and may contribute to resistance to treatment with checkpoint inhibitors. Blocking IL-27 with casdozokitug in clinical trials has led to monotherapy tumor growth inhibition and partial responses in patients with non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC) (NCT04374877). An ongoing trial is studying combinations with PD-(L)1 pathway blockade in NSCLC, and a planned clinical trial will study the triplet combination of IL-27, PD-(L)1, and VEGF pathway blockade in HCC. Casdozokitug has been granted Orphan Drug designation and Fast Track designation for the treatment of refractory hepatocellular carcinoma from the FDA. It is the first IL-27 antibody to enter the clinic. About\u00a0Coherus BioSciences Coherus is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of innovative immunotherapies to treat cancer. Coherus is developing an innovative immuno-oncology pipeline that is expected to be synergistic with its proven commercial capabilities in oncology. Coherus\u2019 immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor immunologic response and enhance outcomes for patients with cancer. Casdozokitug is a novel IL-27 antagonistic antibody currently being evaluated in two ongoing clinical studies: a Phase 1/2 study in advanced solid tumors and a Phase 2 study in hepatocellular carcinoma. CHS-114 is a highly selective, competitively positioned, cytolytic anti-CCR8 antibody currently in a Phase 1 study in patients with advanced solid tumors, including HNSCC. CHS-1000 is a novel humanized Fc-modified IgG1 monoclonal antibody specifically targeting ILT4 (LILRB2). An IND for CHS-1000 was allowed to proceed by the FDA in the second quarter of 2024 and proceeding to the first-in-human clinical study is subject to further evaluation in Coherus\u2019 portfolio prioritization process. Coherus markets LOQTORZI\u00ae (toripalimab-tpzi), a novel next-generation PD-1 inhibitor, and UDENYCA\u00ae (pegfilgrastim-cbqv), a biosimilar of Neulasta. In December 2024, Coherus announced the planned divestiture of its UDENYCA franchise. The transaction is expected to close by the end of the first quarter of 2025. Neulasta\u00ae is a registered trademark of Amgen, Inc. Forward-Looking Statements Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the \"safe harbor\" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Coherus\u2019 expectations about identifying synergies between its I-O pipeline and its commercial operations; statements about new cases and deaths from liver cancer and intrahepatic bile duct cancer in the US; estimates of future enrollment in Coherus\u2019 clinical studies; Coherus\u2019 expectations that its clinical pipeline candidates may extend patient survival and enhance anti-tumor effects; and statements about the closing conditions to consummate the proposed transaction for the divestiture of Coherus\u2019 UDENYCA franchise being satisfied at all or in the estimated time. Such forward-looking statements involve substantial risks and uncertainties that could cause Coherus\u2019 actual results, performance or achievements to differ significantly from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties inherent in the clinical drug development process; risks related to Coherus\u2019 existing and potential collaboration partners; risks of Coherus\u2019 reliance on third-parties; the risks and uncertainties related to manufacturing and supply of Coherus\u2019 products, the risks and uncertainties of the regulatory approval process, including the speed of regulatory review and the timing of Coherus\u2019 regulatory filings; uncertainties as to the timing for completion of the proposed transaction; uncertainties as to Coherus\u2019 ability to obtain the approval of its shareholders required to consummate the proposed transaction for the divestiture of UDENYCA; the possibility that competing offers will be made by third parties; the occurrence of any event, change or other circumstance that may give rise to a right of one or both parties to terminate the agreement to divest UDENYCA; the possibility that the proposed transaction for the divestiture of UDENYCA may not be completed in the time frame expected by Coherus or at all, including due to the possibility that a governmental entity may prohibit, delay, or refuse to grant approval, if required, for the consummation of the proposed transaction to divest UDENYCA (or only grant approval subject to adverse conditions or limitations). All forward-looking statements contained in this press release speak only as of the date of this press release. Unless required by law, Coherus is not under any duty and undertakes no obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, of new information, data or methods, future events or other changes. For a further description of the significant risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Coherus\u2019 business in general, see Coherus\u2019 Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2024 filed with the Securities and Exchange Commission (SEC) on November 6, 2024, including the section therein captioned \u201cRisk Factors\u201d and in other documents Coherus files with the SEC including the preliminary proxy statement of Coherus relating to the proposed transaction for the divestiture of UDENYCA filed with the SEC on January 14, 2025 and, when available, the definitive proxy statement of Coherus relating to the proposed transaction for the divestiture of UDENYCA. UDENYCA \u00ae and LOQTORZI \u00ae , whether or not appearing in large print or with the trademark symbol, are trademarks of Coherus, its affiliates, related companies or its licensors or joint venture partners unless otherwise noted. Trademarks and trade names of other companies appearing in this press release are, to the knowledge of Coherus, the property of their respective owners. References 1 Coherus to Acquire Surface Oncology (2023, June 16) [ Press Release ] 2 Daneng Li et al., JCO 42, 470-470(2024). 3 Yinghong S, et al. Oral presentation at: CSCO 2024; September 27, 2024; Xiamen, China. 4 Project Optimus: Reforming the dose optimization and dose selection paradigm in oncology 5 National Cancer Institute Cancer Stat Facts: Liver and Intrahepatic Bile Duct Cancer; retrieved December 17, 2024, from https://seer.cancer.gov/statfacts/html/livibd.html Coherus Contact Information: For Investors: Jodi Sievers VP, Investor Relations & Corporate Communications IR@coherus.com For Media: Argot Partners (212) 600-1902 coherus@argotpartners.com Ver comentarios Condiciones y Pol\u00edtica de privacidad Privacy Dashboard Historias recomendadas", "symbol": "CHRS", "date": "2025-01-22T15:00:00", "sentiment": {"score": 0.9213669374585152, "confidence": 0.9379425048828125, "probabilities": {"positive": 0.9379425048828125, "negative": 0.016575567424297333, "neutral": 0.04548189416527748}}, "embedding": [0.0032952185720205307, -0.10471953451633453, -0.11337420344352722, -0.0538061261177063, 0.08153854310512543, -0.09203585237264633, -0.23528066277503967, 0.19890129566192627, 0.040346771478652954, 0.06400900334119797, -0.11608392745256424, -0.012421362102031708, 0.1130390614271164, 0.08488617092370987, -0.05894444137811661, 0.137624129652977, 0.10683487355709076, 0.0945001095533371, -0.046232957392930984, 0.03869505226612091, 0.020034395158290863, -0.03147261217236519, 0.0925452783703804, 0.0358552411198616, -0.01849294826388359, -0.023599283769726753, -0.13428416848182678, 0.07143796980381012, -0.25897350907325745, -0.02442944049835205, 0.08379928767681122, -0.01982354372739792, -0.08184663206338882, 0.0560760572552681, -0.03531019017100334, -0.08985123783349991, -0.10188572108745575, 0.10514329373836517, -0.13238029181957245, -0.06355474144220352, -0.13359786570072174, 0.07859575003385544, -0.03883209824562073, -0.0818694531917572, -0.003305496647953987, -0.205677792429924, -0.2203909307718277, 0.05258256196975708, 0.12453524768352509, 0.15340684354305267, -0.03075340762734413, 0.08472047746181488, -0.13293297588825226, 0.27198871970176697, -0.07754774391651154, -0.10191183537244797, -0.07734476029872894, -0.030458316206932068, 0.05555655434727669, -0.018564989790320396, -0.09260344505310059, -0.1022733598947525, 0.11424674093723297, 0.07077199965715408, 0.01901143230497837, 0.029234830290079117, -0.1260237693786621, -0.019271699711680412, -0.11348693072795868, 0.004503526724874973, 0.006695549003779888, -0.0016865497455000877, 0.10610772669315338, 0.04354269802570343, 0.010726062580943108, 0.024934755638241768, 0.16843682527542114, 0.19634577631950378, 0.1112922951579094, -0.14195629954338074, -0.0547986701130867, 0.11616240441799164, 0.05324956774711609, -0.054326869547367096, -0.05494295433163643, 0.032310981303453445, 0.004639246501028538, 0.18712198734283447, 0.10423264652490616, 0.05621489882469177, 0.24475093185901642, 0.1594688892364502, 0.03312017023563385, 0.10424347966909409, 0.0739809200167656, -0.09153668582439423, 0.05893826484680176, 0.03555222600698471, -0.008461689576506615, -0.10054193437099457, 0.03225783631205559, -0.13532160222530365, -0.0013139466755092144, -0.08822816610336304, 0.08342369645833969, 0.012080962769687176, 0.027945715934038162, 0.07759460061788559, 0.06355282664299011, 0.039724238216876984, 0.039250828325748444, -0.04502735286951065, 0.09639659523963928, -0.09631313383579254, 0.05695196986198425, 0.2059953659772873, -0.01861329935491085, 0.035180412232875824, 0.16018101572990417, -0.09973189979791641, 0.09078959375619888, -0.1053059995174408, 0.07220678776502609, -0.1860523819923401, 0.22072526812553406, 0.16714562475681305, 0.03363071754574776, 8.506896129215441e-33, -0.041298769414424896, 0.039115652441978455, 0.15957631170749664, 0.12932747602462769, -0.0009476628620177507, -0.035750649869441986, 0.1283741146326065, 0.11193815618753433, -0.17305117845535278, -0.04851304367184639, -0.11156736314296722, 0.1384688913822174, 0.029372306540608406, 0.07905299216508865, -0.1496824324131012, 0.00010277074761688709, 0.06389620155096054, -0.047561950981616974, -0.17510397732257843, -0.041157450526952744, 0.07235614210367203, -0.023715456947684288, -0.07717510312795639, -0.051497600972652435, -0.000170472776517272, 0.022099725902080536, -0.0264234971255064, 0.20001724362373352, -0.1248667761683464, 0.0027907583862543106, -0.275779664516449, 0.033825188875198364, 0.03282956779003143, 0.018539810553193092, -0.08639495074748993, -0.05056934803724289, 0.0012882803566753864, -0.0030599436722695827, 0.02780897542834282, -0.04079517722129822, 0.11502691358327866, -0.03867364674806595, -0.19626399874687195, -0.05063793063163757, 0.10730554163455963, -0.20057840645313263, -0.044040583074092865, -0.05587943270802498, -0.05636114999651909, 0.06206752359867096, 0.041612714529037476, -0.10834628343582153, -0.01013217680156231, 0.08600564301013947, -0.08814500272274017, 0.02367115393280983, -0.10219712555408478, 0.07807566225528717, 0.11391103267669678, 0.02319183386862278, 0.046054642647504807, -0.021902061998844147, 0.010865524411201477, 0.1553945541381836, -0.027584688737988472, -0.11368320882320404, -0.034867484122514725, 0.019529368728399277, -0.09303145110607147, 0.0817163735628128, -0.08332513272762299, 0.026268834248185158, 0.10218958556652069, 0.0992603451013565, 0.08400234580039978, -0.039763279259204865, -0.0028231022879481316, 0.037740737199783325, -0.030388209968805313, 0.15666502714157104, -0.09056530892848969, -0.08265271782875061, -0.18962343037128448, 0.12415693700313568, -0.05862061306834221, -0.07748446613550186, 0.010178464464843273, -0.022872285917401314, -0.17504745721817017, 0.00886982399970293, 0.12456156313419342, -0.050609029829502106, -0.060912903398275375, 0.10378064215183258, 0.08228443562984467, -1.1467377917077403e-32, 0.014393317513167858, 0.0937633067369461, 0.03822023421525955, 0.004900864325463772, -0.03586418181657791, 0.19280382990837097, 0.1803886741399765, -0.08710097521543503, 0.10641279816627502, -0.268291175365448, 0.03191635385155678, -0.031128451228141785, 0.010275609791278839, -0.07322736084461212, -0.04739854484796524, 0.049521274864673615, -0.08858843147754669, 0.07582981884479523, -0.19577999413013458, 0.11191579699516296, 0.006275944411754608, 0.07318507879972458, -0.11202239245176315, -0.07495874166488647, -0.09756602346897125, -0.0024275006726384163, 0.05557236075401306, -0.03138510882854462, -0.01779954321682453, 0.10159006714820862, 0.1466463804244995, 0.1048828661441803, -0.22075983881950378, 0.0018363166600465775, 0.11381272971630096, -0.017503954470157623, 0.06200094521045685, -0.23372289538383484, -0.0013818657025694847, -0.02410011924803257, -0.03164716809988022, 0.022963495925068855, -0.20484882593154907, -0.03416168689727783, -0.0713232234120369, 0.09706300497055054, 0.07021833956241608, 0.02990534156560898, 0.12838512659072876, -0.04197362810373306, -0.043222300708293915, -0.06452970206737518, -0.06573782116174698, 0.09862624108791351, -0.02834405191242695, 0.0043489933013916016, 0.003943958319723606, 0.0015652799047529697, -0.16959598660469055, 0.16091355681419373, -0.005402301903814077, 0.11009672284126282, -0.0011896248906850815, -0.0930762067437172, 0.12064503878355026, 0.1231958195567131, 0.027774378657341003, -0.09808756411075592, 0.17894449830055237, -0.1434042602777481, -0.08064056932926178, -0.03195241838693619, -0.051093682646751404, 0.020643994212150574, -0.05618763715028763, 0.10881257057189941, 0.09096792340278625, -0.1393260657787323, -0.10622120648622513, -0.025460483506321907, 0.11183136701583862, -0.07560492306947708, 0.03172300010919571, -0.02219928428530693, -0.0685141459107399, 0.1229577362537384, -0.04734228178858757, -0.0788063108921051, -0.08309311419725418, 0.1140797883272171, -0.003790046088397503, -0.04041336476802826, -0.1307520568370819, 0.15622487664222717, -0.09043222665786743, -1.0025699737070681e-07, 0.09098389744758606, -0.08504171669483185, 0.0554618164896965, -0.22422964870929718, -0.06470515578985214, 0.06786234676837921, -0.05800788104534149, -0.08287796378135681, -0.004968471359461546, 0.12321636080741882, 0.15601232647895813, 0.05108512192964554, -0.11317957192659378, 0.048558905720710754, -0.05098837986588478, -0.0006581032648682594, -0.003792363917455077, -0.02025197073817253, 0.008277712389826775, 0.10822804272174835, -0.032284051179885864, -0.1260974109172821, 0.010023212060332298, -0.16783186793327332, 0.13729137182235718, -0.08891847729682922, 0.026840664446353912, 0.12805959582328796, 0.10459522902965546, -0.10205662995576859, -0.10860107094049454, -0.16142114996910095, -0.013896994292736053, -0.015052586793899536, 0.07231125235557556, 0.032538000494241714, 0.005203899461776018, -0.04061606153845787, 0.03982459753751755, 0.10997885465621948, 0.25265195965766907, 0.041801344603300095, -0.09664082527160645, -0.10588999092578888, 0.001965641975402832, 0.01570129580795765, -0.19322434067726135, 0.01468012947589159, -0.0035833159927278757, -0.07681501656770706, -0.1797339767217636, -0.005665176548063755, -0.023801349103450775, -0.11781682074069977, -0.001957012340426445, 0.05753302574157715, -0.09984695911407471, 0.02645036205649376, 0.09968221187591553, -0.1307782381772995, 0.023612920194864273, -0.04190489277243614, 0.010216906666755676, 0.006719166412949562], "changes": {"1wk": -15.267170779417668}}, {"text": "HNO International Targets NASDAQ Uplist and Capital Raise with Respected Investment Banking Firm PR Newswire Tue, Jan 14, 2025, 4:00 PM 4 min read In This Article: HNOI HOUSTON , Jan. 14, 2025 /PRNewswire/ -- HNO International, Inc. (OTC: HNOI), a leader in hydrogen-based clean energy technologies, is pleased to announce the next steps in execution of management's NASDAQ plans with a leading Wall Street investment banking firm to assist with its acquisition strategy, sourcing capital, and NASDAQ uplist process. HNO International, a clean and green hydrogen (PRNewsfoto/HNO International) HNO International has retained the investment banking firm as placement agent and financial advisor for up to $20 million for capital expenditures and future acquisitions through a Reg-A. The investment banking firm is a full-service broker/dealer, and has been providing services to both public and private companies through IPO's, Pre-IPO-Special Vehicles (SPV), Private Placements, Real Estate Investment Trusts, 1031 Tax Exchange Funds and Special Purpose Acquisition Company (SPAC) opportunities since the early 1980's. The Managing Director of the Firm, commented \"The global demands for energy continue to climb at extraordinary rates, prompting the need for additional sources, of which HNO International is set to play a key role. We feel our extensive service portfolio is a great match, one that will take HNO International from the small OTC market space to a global reach, through additional financing and the NASDAQ uplist.\" \"From the start, our goal with HNO International was to build a solid, global-reaching, energy supplier, servicer and energy product development company. The recent invite to be interviewed on the NASDAQ floor (see link) along with this announced engagement of the investment banking firm, further confirms the ground work we've done building a strong company with increasing shareholder value has worked. 2025 is going to be another amazing year for the company and shareholders. We look forward to bringing you all the exciting developments we have in store,\" said Donald Owens , Chairman of the Board of Directors and CEO of HNO International. Recent NASDAQ floor interview: https://www.youtube.com/watch?v=rq3ivXlDSyU About the Investment Banking Firm Founded in the early 1980's the firm is a full-service broker/dealer. Their clients include high net worth individuals from many countries, institutional investors, family offices, managed pension funds and hedge funds. They are committed to servicing each client on a personal level to help meet their individual financial goals. Their belief is that their commitment strengthens client relationships and, in turn, creates long-term associations. The investment banking team has more than 100 years of combined experience. They provide services including Private Placements, PIPEs, Initial and Secondary Public Offerings, Bridge Financing, Merger and Acquisition assistance, market making and the ability to assist with up-listing to national exchanges. They are not content to simply have\u00a0 \"transaction-oriented\" relationships with their clients; they are committed to being the clients' long-term, trusted advisors. Story Continues About HNO International HNO International (HNOI) is a company specializing in the design, integration, and development of green hydrogen-based energy technologies. With over 15 years of experience in green hydrogen production, HNOI and its leadership team are on a mission to help lead the renewable energy transition by making energy accessible to businesses and communities worldwide. Their pioneering solutions, including the Scalable Hydrogen Energy Platform (SHEP TM ) and the Compact Hydrogen Refueling Station (CHRS TM ) , are setting new standards for green hydrogen production. Forward-Looking Statements This news release contains \"forward-looking statements\" which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as \"anticipate\", \"seek\", intend\", \"believe\", \"estimate\", \"plan\", or similar phrases may be deemed \"forward-looking statements\" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K, our quarterly reports on Form 10-Q and other periodic reports filed from time to time with the Securities and Exchange Commission. For more information, please visit www.sec.gov . Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/hno-international-targets-nasdaq-uplist-and-capital-raise-with-respected-investment-banking-firm-302350019.html SOURCE HNO International View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CHRS", "date": "2025-01-14T16:00:00", "sentiment": {"score": 0.7858375879004598, "confidence": 0.7933601140975952, "probabilities": {"positive": 0.7933601140975952, "negative": 0.0075225261971354485, "neutral": 0.19911731779575348}}, "embedding": [-0.05698702484369278, -0.030596060678362846, -0.027524305507540703, 0.007845256477594376, 0.04680594056844711, -0.04589555785059929, 0.08281344175338745, 0.02899428829550743, -0.00031900033354759216, 0.021465472877025604, 0.0004392843693494797, 0.09013848751783371, -0.04308037459850311, -0.02941756881773472, 0.029462140053510666, 0.034038808196783066, 0.01338200643658638, -0.033829305320978165, -0.09570404887199402, -0.03919642046093941, 0.00364319933578372, -0.1607273519039154, 0.004958735313266516, -0.02804037742316723, -0.008454992435872555, -0.006595076993107796, -0.018032148480415344, 0.14072924852371216, -0.1739310324192047, -0.0782044380903244, 0.020206764340400696, 0.1753372848033905, 0.0014380337670445442, -0.10568627715110779, 0.05105816572904587, 0.19028528034687042, -0.0824364721775055, 0.002741931937634945, 0.043495215475559235, -0.03695937246084213, 0.08559045940637589, -0.13777518272399902, -0.0587112158536911, -0.000953566050156951, 0.02343158982694149, -0.09966690838336945, 0.03502611070871353, 0.011528675444424152, 0.01753927767276764, -0.09284169971942902, -0.14910823106765747, -0.0444878488779068, 0.11547018587589264, -0.06288385391235352, -0.03374577686190605, 0.17186245322227478, -0.09085634350776672, -0.03183348476886749, 0.12027587741613388, -0.08516828715801239, -0.004017476923763752, -0.07073871791362762, 0.05204528570175171, -0.032982196658849716, 0.2306707799434662, -0.08632272481918335, 0.07173238694667816, 0.09639118611812592, -0.004452325403690338, -0.11341370642185211, 0.14302216470241547, -0.09984660148620605, -0.12694686651229858, -0.08381179720163345, -0.060567572712898254, 0.11551624536514282, 0.14531993865966797, 0.1519174426794052, 0.1328309178352356, -0.17559698224067688, 0.1578708440065384, 0.1152852326631546, -0.03673715144395828, -0.09917657822370529, -0.10793951898813248, 0.032963573932647705, 0.04828610271215439, -0.05956099182367325, 0.03226662427186966, 0.028332363814115524, 0.04977232962846756, -0.07571950554847717, -0.03497130423784256, -0.03976801782846451, 0.11607332527637482, 0.02069631591439247, -0.08544738590717316, 0.058796171098947525, 0.0019660284742712975, -0.0025820122100412846, 0.14098253846168518, 0.0873408168554306, -0.12959825992584229, 0.009626389481127262, -0.17755615711212158, -0.08402456343173981, -0.02684556134045124, 0.028480853885412216, 0.10559017956256866, 0.038666609674692154, -0.13644036650657654, 0.07583099603652954, -0.13879652321338654, -0.13970708847045898, -0.08404579758644104, 0.05077531188726425, -0.04782043397426605, -0.036801159381866455, 0.14662595093250275, -0.22804443538188934, -0.0020584994927048683, 0.11525784432888031, -0.10312755405902863, -0.09836778044700623, 0.00204385444521904, -0.07832406461238861, -0.16630659997463226, 9.4768971697827e-33, -0.09259934723377228, 0.10605975985527039, -0.010895379818975925, -0.0017720013856887817, -0.07240593433380127, -0.0022324530873447657, 0.0029517216607928276, 0.07346154749393463, -0.13683833181858063, -0.027662072330713272, -0.14189058542251587, 0.08954088389873505, -0.040074802935123444, -0.09213388711214066, -0.11238527297973633, -0.20756101608276367, 0.01336820051074028, 0.10742688179016113, 0.0358913391828537, 0.02053872123360634, -0.028126990422606468, 0.12410499900579453, -0.0224201250821352, 0.0399741604924202, 0.1559126228094101, -0.03153174743056297, 0.05611409246921539, -0.19935932755470276, 0.034736279398202896, 0.07393041998147964, 0.0013406507205218077, 0.048386383801698685, -0.02566777728497982, 0.045584555715322495, -0.07066522538661957, -0.10434860736131668, -0.21815353631973267, -0.12456785887479782, -0.022664159536361694, -0.03351185470819473, -0.09339381754398346, 0.15431375801563263, -0.1375662386417389, 0.06012629717588425, -0.00366687448695302, 0.12097842246294022, 0.025406580418348312, 0.03156864270567894, 0.04128028452396393, 0.026047449558973312, -0.13174286484718323, 0.0011910325847566128, -0.08144907653331757, -0.09259428083896637, 0.021421099081635475, -0.07533778250217438, 0.06518803536891937, -0.0731474906206131, 0.09299097955226898, 0.12515196204185486, -0.11857771873474121, 0.15960431098937988, -0.1809615194797516, 0.08539917320013046, -0.03788764774799347, 0.1737062633037567, -0.03557182475924492, -0.0029163381550461054, 0.04353194683790207, 0.0061899046413600445, 0.03958819434046745, -0.056792549788951874, 0.2010813057422638, 0.012921449728310108, 0.06049857288599014, -0.08841060101985931, -0.013451552018523216, 0.04861675202846527, 0.03441666066646576, -0.003481508232653141, 0.013653997331857681, -0.0015919571742415428, 0.12519404292106628, 0.046438638120889664, 0.005382893607020378, -0.047550708055496216, 0.04395493119955063, -0.09700261801481247, 0.052279770374298096, 0.038080986589193344, 0.01605299673974514, -0.05916319414973259, 0.045753419399261475, 0.10894113779067993, 0.033144760876894, -8.656876718752888e-33, 0.06816384196281433, -0.12442731857299805, -0.08821217715740204, -0.08646734058856964, -0.039996352046728134, 0.050167374312877655, 0.04298946261405945, -0.045470353215932846, 0.016306042671203613, -0.1027269959449768, 0.04032765328884125, -0.05812777578830719, -0.03409421816468239, 0.03687158226966858, -0.08138897269964218, -0.01757940463721752, 0.029450684785842896, -0.08882296830415726, -0.05278218537569046, 0.06727176904678345, 0.08206933736801147, 0.16619595885276794, -0.05847863107919693, 0.146951824426651, 0.010193388909101486, 0.024960152804851532, 0.11235551536083221, 0.14045600593090057, 0.11876048892736435, 0.0005673374980688095, -0.12721724808216095, -0.040841370820999146, -0.22100459039211273, 0.18619178235530853, 0.01554589718580246, -0.0008018175140023232, 0.11316144466400146, 0.007879011332988739, -0.07974663376808167, 0.05492245778441429, 0.06675217300653458, -0.045741382986307144, 0.007984722964465618, -0.03436058759689331, -0.11553812772035599, 0.005536945536732674, -0.04759664833545685, -0.005912996828556061, -0.043427616357803345, -0.006607899442315102, 0.009842751547694206, 0.04743599146604538, -0.01509310957044363, 0.05915773659944534, -0.09632683545351028, 0.10035592317581177, 0.09620653092861176, 0.07882760465145111, -0.010868353769183159, 0.013488078489899635, 0.09413022547960281, 0.12151449918746948, 0.08465828001499176, 0.11403760313987732, 0.01595410704612732, -0.016028108075261116, 0.04675815626978874, -0.10707806050777435, -0.04566805809736252, -0.2584547996520996, -0.06312549114227295, -0.11096033453941345, 0.03295035660266876, -0.05197850987315178, -0.040244169533252716, 0.059723637998104095, -0.003963667433708906, -0.2158484160900116, 0.0037093358114361763, -0.018873505294322968, -0.12199023365974426, 0.11944995075464249, -0.029270298779010773, 0.09802968800067902, 0.1905127763748169, 0.04775278642773628, 0.02050088718533516, -0.05225434899330139, 0.033420536667108536, -0.024335356429219246, 0.06388947367668152, -0.10356055200099945, -0.07181917130947113, 0.1038450300693512, -0.028080333024263382, -1.0001903660850076e-07, -0.033010467886924744, -0.0684288963675499, 0.03302352875471115, 0.06256583333015442, 0.16247248649597168, -0.14711888134479523, 0.047905921936035156, 0.09393302351236343, 0.0795070230960846, 0.19001483917236328, 0.15558302402496338, 0.07253497838973999, -0.13560187816619873, -0.045424241572618484, -0.07263720780611038, -0.038605697453022, -0.03618650138378143, 0.05336884409189224, -0.0646260529756546, 0.006247274577617645, 0.023741407319903374, 0.061674509197473526, -0.010289831086993217, 0.012884564697742462, 0.05731943994760513, -0.08673732727766037, 0.07725310325622559, 0.04324858635663986, 0.09336303919553757, -0.09149660915136337, 0.011819195002317429, -0.03319019079208374, 0.12934046983718872, -0.001913696527481079, 0.003163659945130348, 0.0563078448176384, 0.1405659019947052, 0.10032132267951965, -0.07267802953720093, 0.06958670169115067, -0.09394221007823944, -0.08268578350543976, 0.019617917016148567, -0.030241521075367928, 0.003361433744430542, -0.09760183840990067, -0.33064505457878113, -0.01870793104171753, 0.1472587287425995, -0.07112840563058853, -0.03126154839992523, 0.00780603289604187, 0.07522667199373245, 0.10239308327436447, 0.12847161293029785, 0.0018719378858804703, -0.10056119412183762, -0.03097529709339142, -0.018509995192289352, 0.1278681457042694, 0.18766717612743378, -0.11373821645975113, 0.0024581504985690117, 0.1574467122554779], "changes": {"1wk": -3.472227051302047}}, {"text": "Coherus Management to Present at the 43rd Annual J.P. Morgan Healthcare Conference Coherus BioSciences, Inc. Wed, Jan 8, 2025, 4:00 PM 1 min read In This Article: CHRS Coherus BioSciences, Inc. REDWOOD CITY, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc.\u00a0(\u201cCoherus,\u201d NASDAQ: CHRS) today announced that senior management will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 5:15 p.m. Pacific Time. The presentation and Q&A session will be accessible via Webcast through a link posted on the Investor Events Calendar section of the Coherus website: https://investors.coherus.com/events-presentations . This webcast will be available for replay until\u00a0February 10, 2025. Coherus Contact Information: For Investors: Jodi Sievers VP, Investor Relations & Corporate Communications IR@coherus.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CHRS", "date": "2025-01-08T16:00:00", "sentiment": {"score": 0.0047533027827739716, "confidence": 0.025873379781842232, "probabilities": {"positive": 0.025873379781842232, "negative": 0.02112007699906826, "neutral": 0.9530065655708313}}, "embedding": [-0.031889379024505615, 0.0543624609708786, -0.07694777846336365, -0.008144007995724678, -0.0022313427180051804, 0.044163405895233154, -0.11549977958202362, -0.03921450674533844, 0.059956759214401245, -0.05343371629714966, -0.03751209005713463, 0.016831273213028908, -0.08361458778381348, 0.01558390911668539, -0.007509801536798477, -0.14055778086185455, 0.08952996879816055, -0.2199835330247879, 0.01269523985683918, -0.10109005868434906, -0.01575871929526329, 0.04058190435171127, -0.015336168929934502, 0.05387406423687935, -0.07178522646427155, -0.11458121985197067, -0.03853197768330574, -0.04986871778964996, 0.011736002750694752, 0.040743496268987656, 0.007869737222790718, -0.01651042141020298, 0.017763838171958923, -0.0012183092767372727, 0.0063845026306807995, 0.05620894953608513, 0.01734376884996891, -0.06870722025632858, 0.06297106295824051, 0.1422520875930786, -0.03570936247706413, -0.0364757664501667, -0.06495191156864166, 0.04855760186910629, -0.0034015204291790724, -0.023993879556655884, -0.09316293895244598, -0.031029436737298965, -0.04529045522212982, 0.09580954164266586, -0.1435406655073166, -0.10919189453125, 0.09190340340137482, -0.0785507783293724, -0.05850827693939209, 0.10579054057598114, -0.17388276755809784, -0.0664469450712204, 0.0367877371609211, -0.1762860119342804, 0.09187088161706924, -0.0976538136601448, 0.0852167084813118, 0.2232564091682434, 0.01777389645576477, 0.05131153762340546, 0.0959722101688385, 0.15494009852409363, 0.04688866063952446, -0.14686867594718933, 0.04004191979765892, -0.06581541895866394, -0.05812392383813858, -0.08683294802904129, 0.017176758497953415, 0.14655449986457825, -0.07936720550060272, 0.06095157191157341, 0.18509070575237274, -0.10152506828308105, 0.01685258373618126, -0.011815130710601807, 0.02672002837061882, 0.04018858075141907, 0.041134148836135864, 0.054500702768564224, -0.006483231671154499, 0.10788083076477051, -0.11356926709413528, -0.11510614305734634, 0.028898019343614578, -0.07927202433347702, 0.02987578697502613, 0.044385962188243866, -0.13565227389335632, 0.037175796926021576, -0.01257370039820671, -0.02833048813045025, -0.013509455136954784, -0.05721471831202507, -0.0579904168844223, 0.17388129234313965, -0.028204988688230515, 0.05805065855383873, -0.14452853798866272, -0.06495257467031479, -0.04801052063703537, 0.10860078781843185, 0.21455518901348114, 0.10938438773155212, -0.15535968542099, 0.21067535877227783, 0.05998793989419937, -0.10251938551664352, 0.04997590556740761, 0.23500555753707886, -0.02333359234035015, 0.02554962784051895, 0.2224881500005722, -0.08614494651556015, 0.13634654879570007, -0.057411693036556244, -0.10686157643795013, -0.11159507930278778, -0.042992059141397476, 0.12433760613203049, -0.08518055081367493, 9.092958674285063e-33, 0.05407409742474556, 0.09083305299282074, 0.1975059062242508, 0.02032579481601715, 0.0798792839050293, -0.10012628883123398, 0.02995290979743004, -0.08329758048057556, -0.041889410465955734, -0.07070872187614441, -0.10545488446950912, 0.1268101930618286, 0.097530797123909, -0.07568784058094025, -0.19982771575450897, -0.15368250012397766, -0.12682873010635376, 0.06813132762908936, -0.08081507682800293, 0.022195491939783096, 0.005057604983448982, 0.028292102739214897, -0.035616349428892136, 0.23011983931064606, 0.1625945270061493, -0.016195496544241905, 0.011663276702165604, 0.057702284306287766, 0.1243206188082695, 0.08561215549707413, -0.10319333523511887, -0.059399545192718506, -0.08561531454324722, -0.09651733189821243, -0.07663384824991226, 0.025052249431610107, -0.15099845826625824, -0.19705165922641754, -0.011996379122138023, -0.1573255956172943, -0.012721574865281582, -0.03127436339855194, -0.04824994131922722, -0.07092559337615967, -0.027513980865478516, -0.03162169083952904, 0.014360176399350166, -0.018665121868252754, 0.046546820551157, -0.09113696217536926, -0.22120912373065948, 0.0447552390396595, -0.046069592237472534, -0.06435339152812958, 0.13072602450847626, -0.06278081983327866, 0.018661580979824066, -0.12265024334192276, -0.018352920189499855, 0.043587956577539444, 0.19031383097171783, 0.17218604683876038, -0.03368477150797844, 0.037516482174396515, -0.1870298534631729, 0.05134481191635132, -0.13032208383083344, -0.02211103029549122, 0.000367127446224913, 0.10213727504014969, 0.08254996687173843, 0.07007245719432831, -0.0456913597881794, -0.045056525617837906, 0.10343277454376221, 0.01614135503768921, 0.09635450690984726, 0.02126624621450901, 0.007217302918434143, 0.07389067858457565, 0.12539483606815338, -0.024667980149388313, 0.05591154471039772, 0.1251664161682129, 0.1101587638258934, -0.04810323193669319, 0.039755843579769135, 0.03264873847365379, -0.042708948254585266, 0.11276502907276154, 0.024568209424614906, 0.11067869514226913, 0.17158952355384827, 0.21735262870788574, -0.11699950695037842, -1.1230532703118005e-32, 0.03965087607502937, 0.007048146333545446, -0.023398995399475098, -0.12219581753015518, -0.004877201281487942, 0.04006773978471756, 0.10585199296474457, -0.029759014025330544, 0.1338953822851181, -0.23123595118522644, 0.07253048568964005, 0.04970278590917587, -0.00020383441005833447, 0.023796502500772476, -0.07901817560195923, 0.1170237734913826, 0.06480774283409119, -0.04897168278694153, -0.04277360439300537, 0.0605095811188221, 0.07707101851701736, 0.06317245215177536, -0.047998636960983276, -0.030105380341410637, 0.023391660302877426, 0.04798302799463272, 0.12658287584781647, -0.01219106838107109, -0.08334353566169739, -0.11320850998163223, -0.1055862307548523, -0.17575211822986603, -0.162610724568367, 0.13931503891944885, -0.07203570008277893, -0.007319743279367685, 0.09031965583562851, -0.07739377021789551, -0.004661074373871088, -0.12662631273269653, 0.11388617008924484, -0.07248588651418686, -0.09596315026283264, 0.1082727313041687, 0.07018038630485535, 0.023508846759796143, -0.12048536539077759, -0.023472703993320465, -0.0025932281278073788, 0.06840543448925018, -0.172636479139328, 0.024449961259961128, -0.06272998452186584, 0.03211386501789093, -0.010973806492984295, 0.13215042650699615, 0.007220786530524492, 0.0015207335818558931, -0.09295779466629028, 0.055800117552280426, -0.03922246769070625, 0.1487606316804886, -0.09143051505088806, 0.08560600131750107, 0.04276116192340851, -0.005076325498521328, 0.07403264939785004, 0.06626668572425842, -0.06471472233533859, -0.05421704798936844, 0.11481271684169769, -0.01896034926176071, -0.11394686996936798, -0.10729114711284637, 0.03341451659798622, 0.05498407036066055, -0.104292131960392, -0.07626279443502426, -0.19272488355636597, 0.016853563487529755, -0.018103566020727158, 0.06810151040554047, 0.018331943079829216, 0.11743571609258652, 0.03911199793219566, 0.08596455305814743, 0.05590053275227547, -0.05512430891394615, -0.016054866835474968, 0.012124409899115562, -0.09818968176841736, -0.12297775596380234, -0.05055971443653107, 0.05320967361330986, 0.09241970628499985, -9.976255199717343e-08, 0.02810150757431984, 0.014978716149926186, 0.09496793150901794, -0.20251119136810303, 0.006476144306361675, -0.13407208025455475, 0.045008543878793716, -0.16911056637763977, -0.025572290644049644, 0.06037600338459015, 0.06012587621808052, 0.043883584439754486, -0.04636988788843155, 0.04154675826430321, -0.05827362835407257, -0.04802075773477554, -0.18632543087005615, 0.06944441795349121, 0.02202453650534153, -0.165569469332695, -0.03761566802859306, -0.08407919853925705, 0.1932954341173172, 0.10117614269256592, 0.006347020156681538, 0.06745310872793198, 0.09218153357505798, 0.038942575454711914, 0.030806297436356544, -0.05988972261548042, -0.1345798373222351, 0.04831605404615402, 0.040664155036211014, 0.031137751415371895, -0.051919516175985336, -0.11311525106430054, -0.10292934626340866, 0.10894936323165894, 0.062041208148002625, 0.07499480247497559, -0.10942288488149643, -0.03131333738565445, -0.043235380202531815, 0.13130785524845123, 0.15329046547412872, 0.06154311075806618, -0.08824452757835388, 0.00816312339156866, 0.02552500180900097, -0.06329534202814102, -0.02702496200799942, -0.05289221554994583, 0.12695114314556122, 0.09485524147748947, -0.023083720356225967, 0.11664467304944992, -0.007202512118965387, -0.08052575588226318, -0.0710090696811676, -0.08588390797376633, 0.14796914160251617, -0.07421636581420898, -0.05297918990254402, 0.05996318906545639], "changes": {"1wk": -4.635757197675371}}, {"text": "PREMIUM Coherus BioSciences to Divest Udenyca to Intas Pharmaceuticals for Up to $558 Million MT Newswires Tue, Dec 3, 2024, 3:47 PM 1 min read In This Article: CHRS Coherus BioSciences (CHRS) said Tuesday that it has agreed to divest its biosimilar drug Udenyca, wh PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CHRS", "date": "2024-12-03T15:47:22", "sentiment": {"score": 0.04733764939010143, "confidence": 0.05934666469693184, "probabilities": {"positive": 0.05934666469693184, "negative": 0.012009015306830406, "neutral": 0.9286443591117859}}, "embedding": [-0.1718820184469223, -0.11805661022663116, -0.07301221042871475, -0.07368312031030655, 0.07832910120487213, -0.17713063955307007, -0.1502598375082016, 0.18968123197555542, 0.0034149016719311476, 0.1036745011806488, 0.0354466587305069, -0.04550175741314888, -0.0695301815867424, 0.09326901286840439, -0.13197530806064606, -0.06631592661142349, 0.01900719478726387, -0.1783311814069748, -0.041502222418785095, 0.05337187275290489, -0.02412627823650837, 0.151932030916214, -0.04844549298286438, -0.016986005008220673, 0.012728399597108364, -0.11043206602334976, -0.02608899399638176, -0.12069858610630035, 0.021680820733308792, -0.13755568861961365, 0.16357983648777008, 0.02357490547001362, 0.09681319445371628, -0.10636881738901138, 0.11805211752653122, -0.03780902549624443, -0.05924577638506889, -0.12920549511909485, 0.023178771138191223, 0.1296617090702057, 0.10540302097797394, -0.16028377413749695, -0.1510608047246933, 0.057737525552511215, -0.07401148229837418, -0.20824508368968964, -0.10979381948709488, -0.0028697834350168705, 0.16167965531349182, 0.10418328642845154, -0.059603236615657806, -0.1962512880563736, -0.05451854690909386, 0.041060928255319595, -0.07899562269449234, -0.08151799440383911, -0.2391403466463089, -0.08209215104579926, 0.01884392648935318, -0.09129912406206131, 0.2407745122909546, -0.07622531056404114, 0.003009212203323841, 0.1565001904964447, -0.13027115166187286, 0.029767842963337898, 0.09673184901475906, 0.023383675143122673, 0.045764531940221786, -0.11874991655349731, 0.014969282783567905, -0.06063351035118103, -0.017492547631263733, 0.03432350978255272, 0.09296747297048569, 0.1644437611103058, 0.15272113680839539, -0.06450145691633224, 0.06627747416496277, -0.20074999332427979, 0.10321565717458725, -0.014455100521445274, 0.07061155140399933, -0.021491652354598045, 0.056483957916498184, 0.05196073651313782, 0.037779174745082855, -0.01566372439265251, 0.05131375789642334, -0.16233596205711365, 0.19635342061519623, -0.0960792675614357, 0.05176003649830818, -0.028231916949152946, -0.2425490915775299, -0.07055703550577164, -0.12203779071569443, -0.02134122885763645, -0.11694512516260147, -0.07336609065532684, -0.008727298118174076, 0.09261736273765564, -0.16272908449172974, -0.20416775345802307, -0.14602775871753693, -0.15038390457630157, 0.08170966804027557, 0.09325868636369705, 0.1866438090801239, 0.25726550817489624, -0.1516808271408081, 0.2630966305732727, 0.11154727637767792, -0.052178554236888885, -0.07492610067129135, 0.30370965600013733, -0.14873385429382324, -0.10076379776000977, 0.21186292171478271, -0.19165168702602386, -0.0371481329202652, 0.03615523502230644, -0.024406414479017258, -0.022466380149126053, 0.049341727048158646, 0.03658177703619003, -0.07764583081007004, 1.1907284637353566e-32, -0.08061136305332184, 0.15651103854179382, 0.01302308402955532, -0.1118733361363411, 0.013071974739432335, -0.028132522478699684, 0.10041522979736328, -0.10410625487565994, -0.15658338367938995, -0.12236782908439636, -0.28971680998802185, 0.19974203407764435, -0.11862644553184509, 0.21822704374790192, -0.16146329045295715, -0.1288442611694336, -0.050789665430784225, 0.13348621129989624, 0.04350103437900543, 0.031892575323581696, 0.11314606666564941, 0.07379339635372162, -0.06948766857385635, 0.042913682758808136, 0.07595501095056534, 0.017830653116106987, -0.009601849131286144, 0.019764164462685585, 0.2621498703956604, 0.061044156551361084, -0.23770877718925476, -0.05110376700758934, -0.01832924596965313, -0.05696434527635574, 0.024092165753245354, 0.06407495588064194, -0.04113767296075821, -0.12240395694971085, 0.054727617651224136, -0.05323902890086174, 0.030867697671055794, 0.05698389932513237, -0.1427215188741684, -0.10696285963058472, 0.05094776675105095, 0.07321994006633759, -0.10479377955198288, -0.04480449855327606, 0.0028766002506017685, -0.12279783189296722, -0.06987302005290985, 0.11425195634365082, -0.17842888832092285, 0.009809639304876328, -0.009921680204570293, 0.01575511321425438, -0.048323217779397964, -0.09737556427717209, 0.19554734230041504, 0.00270974007435143, 0.15477792918682098, 0.14877119660377502, 0.12719011306762695, 0.0011362922377884388, -0.13555452227592468, 0.10377554595470428, -0.13561411201953888, -0.042726438492536545, -0.10840129852294922, 0.06693349778652191, 0.006147267762571573, -0.0675194188952446, -0.03612002730369568, 5.2058272558497265e-05, 0.003493043826892972, -0.030407223850488663, 0.013976950198411942, 0.04173600673675537, 0.15174908936023712, 0.08084797859191895, 0.07899467647075653, -0.05046612024307251, 0.17414884269237518, 0.13973844051361084, 0.11206885427236557, 0.05335434153676033, 0.058283090591430664, 0.09462032467126846, -0.04437514767050743, 0.12432534247636795, 0.04925590008497238, 0.01817120797932148, -0.13197627663612366, -0.05367863550782204, -0.03278164938092232, -1.6975299226545269e-32, -0.05721277743577957, -0.03866397961974144, -0.021473728120326996, -0.033589594066143036, -0.016160352155566216, 0.015465306118130684, -0.08445163071155548, 0.18008337914943695, 0.25722062587738037, -0.12895618379116058, 0.07654725015163422, 0.0603768490254879, 0.0037003594916313887, -0.08985356986522675, 0.04938497021794319, 0.06884364783763885, 0.06459259986877441, -0.037427932024002075, -0.1616068333387375, -0.01596272736787796, -0.1342637836933136, 0.13995446264743805, -0.06106192246079445, 0.1234104335308075, 0.050319891422986984, -0.02515961043536663, 0.12058127671480179, 0.16202105581760406, 0.054960742592811584, -0.031094899401068687, -0.0417819507420063, 0.0056999134831130505, -0.3447180986404419, 0.07617396116256714, -0.12594817578792572, 0.10558909922838211, 0.16512838006019592, -0.03395916521549225, -0.03846793994307518, -0.023285867646336555, 0.06398878991603851, -0.1538437306880951, -0.23484010994434357, 0.07444921880960464, 0.008773919194936752, -0.10021267831325531, -0.11745434254407883, -0.11160943657159805, 0.05166684836149216, 0.045914337038993835, 0.05265824869275093, 0.03601678088307381, 0.14858761429786682, -0.0194429699331522, -0.06211160495877266, 0.10528016090393066, 0.10966825485229492, 0.0006946905632503331, 0.03361537680029869, -0.06087632104754448, 0.09550657123327255, 0.1574348658323288, -0.28489306569099426, -0.060439325869083405, -0.0034507960081100464, 0.07886791229248047, 0.013946994207799435, -0.058625925332307816, -0.11440899223089218, -0.06463151425123215, 0.18971127271652222, -0.0873260572552681, -0.054259251803159714, -0.1756177693605423, 0.04730885848402977, 0.09279557317495346, -0.13450677692890167, -0.0330548994243145, -0.07461000233888626, -0.002431059256196022, -0.058246832340955734, -0.1484965980052948, 0.18265558779239655, -0.010620065033435822, 0.0709192305803299, 0.01927168108522892, 0.0947980210185051, -0.2857011556625366, -0.18111878633499146, 0.04532577097415924, -0.17917954921722412, -0.2024630457162857, -0.10528316348791122, 0.11404569447040558, 0.17545096576213837, -1.0095170921431418e-07, 0.16654109954833984, -0.0564127191901207, 0.03536045551300049, 0.02201131545007229, -0.012281382456421852, -0.08401571214199066, -0.1128082349896431, 0.07983051240444183, -0.07646960020065308, 0.2102610021829605, 0.030106795951724052, 0.019111352041363716, -0.05042053759098053, 0.14627109467983246, -0.03193064033985138, 0.07912710309028625, 0.021599654108285904, 0.10051772743463516, 0.020647289231419563, -0.15628200769424438, -0.10816873610019684, 0.11242330819368362, 0.09990429878234863, -0.05864690989255905, 0.1151675209403038, 0.0670395940542221, 0.1550959348678589, 0.05597223341464996, 0.15340401232242584, -0.02796342596411705, -0.04878474026918411, 0.014804001897573471, -0.057454805821180344, 0.11521728336811066, 0.03797898814082146, -0.0024598613381385803, -0.01255817711353302, 0.10175369679927826, -0.07561206817626953, 0.07639854401350021, -0.04507696256041527, 0.014890491962432861, -0.07684306055307388, 0.1148703396320343, -0.050290897488594055, 0.0667959600687027, -0.082020603120327, -0.05172015354037285, 0.17085781693458557, -0.09053829312324524, 0.12271909415721893, -0.10990124940872192, 0.11108914762735367, -0.019572753459215164, -0.009318926371634007, 0.1100095734000206, -0.18082387745380402, 0.001712730503641069, -0.12978893518447876, 0.046449899673461914, 0.018224641680717468, -0.1783454567193985, 0.11742686480283737, -0.00981861911714077], "changes": {"1wk": -0.5847947508874469, "1mo": -19.29824769319573}}, {"text": "Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025 Coherus BioSciences, Inc. Wed, Dec 18, 2024, 4:30 PM 9 min read In This Article: CHRS Coherus BioSciences, Inc. - Randomized Phase 2 study initiated evaluating the combination of casdozokitug, toripalimab and bevacizumab in patients with liver cancer - REDWOOD CITY, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc.\u00a0(\u201cCoherus,\u201d NASDAQ: CHRS) today announced that an abstract highlighting final clinical and biomarker data from its Phase 2 clinical trial evaluating casdozokitug (casdozo), a selective and potent IL-27-antagonistic antibody, in combination with atezolizumab (atezo) and bevacizumab (bev) in treatment na\u00efve patients with unresectable locally advanced or metastatic hepatocellular carcinoma (HCC), has been selected for a poster presentation at the upcoming 2025 ASCO GI Annual Meeting, being held January 23-25, 2025, in San Fransisco, CA. \u201cCasdozo is a first-in-class antibody, and in oncology, is the first IL-27 cytokine antagonist to demonstrate monotherapy responses and immune activation with a safety profile that lends itself to combination,\u201d said Rosh Dias, M.D., Coherus\u2019 Chief Medical Officer. \u201cWe look forward to sharing the final data from this Phase 2 combination study of casdozo with standard of care with the medical community at the upcoming 2025 ASCO-GI annual meeting. We now have data across several tumor types for casdozo demonstrating clinical activity. We are particularly excited about HCC given the strong preclinical package for targeting IL-27 in liver cancer and now translation to the clinic.\u201d Coherus has initiated a new randomized Phase 2 study ( NCT06679985 ) evaluating casdozo, in combination with bevacizumab and toripalimab, Coherus\u2019 next-generation anti-PD-1 monoclonal antibody, in participants with first-line HCC. This randomized, parallel, open-label Phase 2 study is designed to evaluate the safety, efficacy, and Project Optimus 1 dosing of the triplet combination. The study is expected to enroll up to 72 patients, who will be randomized to receive one of two biologically active doses of casdozo with toripalimab plus bevacizumab or toripalimab plus bevacizumab without casdozo. \u201cAdvancing casdozo development in first-line HCC with a randomized Phase 2 combination study marks a significant milestone in our strategic path to progress our clinical pipeline, which is focused on overcoming immune suppression in the tumor microenvironment to extend survival and improve outcomes for patients and pursuing new indications for toripalimab in the U.S.,\u201d continued Dr. Dias. \u201cCasdozo has shown encouraging responses in the first line setting when added to the existing standard of care, atezolizumab and bevacizumab, and we\u2019re excited to build upon these data with this new Phase 2 study evaluating casdozo in combination with toripalimab and bevacizumab.\u201d Story Continues In the Phase 3 HEPATORCH study, conducted by Junshi Biosciences, patients with advanced HCC treated with toripalimab combined with bevacizumab as a first-line therapy showed significantly better clinical efficacy than sorafenib monotherapy. 2 HEPATORCH patients showed an objective response rate of 25.3% versus 6.1% in the sorafenib group, a median progression-free survival of 5.8 months, and a median overall survival of 20 months, compared to 4 and 14.5 months, respectively, for the sorafenib group. 3 Toripalimab in combination with bevacizumab was well tolerated, with a toxicity profile consistent with the known toxicity profile of each monotherapy, with no new safety signals identified. 3 The results of the HEPATORCH study support the clinical study of toripalimab in combination with bevacizumab as a new first-line treatment option for advanced HCC which, along with the results from the Phase 2 casdozo study reported to date, support pursuing a triple combination of casdozo with toripalimab plus bevacizumab in patients with advanced or metastatic HCC. ASCO-GI 2025 Presentation Details Title: Results from a phase 2 study of triplet blockade of the IL-27, PD-(L)1, and VEGF pathways with casdozokitug (casdozo, CHS-388) in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (uHCC) Lead Author: Daneng Li, City of Hope National Comprehensive Cancer Center Abstract #: 605 Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract Date and Time: Friday, January 24, 2025; 11:30 a.m. \u2013 1:00 p.m. PT Hepatobiliary cancers include a spectrum of invasive carcinomas arising in the liver (hepatocellular carcinoma; HCC), gall bladder, and bile ducts (collectively called biliary tract cancers). The most common type of primary liver cancer in adults is HCC (accounting for ~90%), which is the third leading cause of cancer-related deaths worldwide. According to the NCI Surveillance, Epidemiology and End Results Program (SEER), there will be an estimated 41,630 new cases and 29,840 deaths from liver and intrahepatic bile duct cancer in the US in 2024. 4 The U.S. 5-year relative survival rate for liver and intrahepatic bile duct cancer is 21.7%. 4 The liver cancer treatment pattern has changed in recent years with the emergence of immunotherapy combinations and will continue to evolve as more treatment options become available for these highly lethal cancers. About\u00a0Coherus BioSciences Coherus is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of innovative immunotherapies to treat cancer. Coherus is developing an innovative immuno-oncology pipeline that is expected to be synergistic with toripalimab and its proven commercial capabilities in oncology. Coherus\u2019 immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor immunologic response and enhance outcomes for patients with cancer, particularly patients underserved by current immunotherapy treatments. Casdozokitug is a novel IL-27 antagonistic antibody being evaluated in two ongoing clinical studies: a Phase 1/2 study in advanced solid tumors and a Phase 2 study in hepatocellular carcinoma. CHS-114 is a highly selective, competitively positioned, cytolytic anti-CCR8 antibody currently in a Phase 1 study in patients with advanced solid tumors, including HNSCC. CHS-1000 is a novel humanized Fc-modified IgG1 monoclonal antibody specifically targeting ILT4 (LILRB2). An IND for CHS-1000 was allowed to proceed by the FDA in the second quarter of 2024 and proceeding to the first-in-human clinical study is subject to further evaluation in our portfolio prioritization process. Coherus markets LOQTORZI\u00ae (toripalimab-tpzi), a novel next-generation PD-1 inhibitor, and UDENYCA\u00ae (pegfilgrastim-cbqv), a biosimilar of Neulasta. In December 2024, Coherus announced that it entered into an agreement for the divestiture of the UDENYCA franchise. The proposed transaction is expected to close by the end of the first quarter of 2025. Neulasta\u00ae is a registered trademark of Amgen, Inc. Forward-Looking Statements Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the \"safe harbor\" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Coherus\u2019 expectations about identifying synergies between its I-O pipeline and its commercial operations and its I-O pipeline and toripalimab; future enrollment estimates for Coherus\u2019 clinical studies; Coherus\u2019 expectations that it will be able to demonstrate that its clinical pipeline candidates can extend patient survival; and the ability to satisfy the closing conditions to consummate the proposed transaction for the divestiture of the UDENYCA franchise at all or in the estimated time. Such forward-looking statements involve substantial risks and uncertainties that could cause Coherus\u2019 actual results, performance or achievements to differ significantly from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties inherent in the clinical drug development process; risks related to Coherus\u2019 existing and potential collaboration partners; risks of Coherus\u2019 reliance on third-parties; the risks and uncertainties related to manufacturing and supply of Coherus\u2019 products, the risks and uncertainties of the regulatory approval process, including the speed of regulatory review and the timing of Coherus\u2019 regulatory filings; uncertainties as to the timing for completion of the proposed transaction; uncertainties as to the Company\u2019s ability to obtain the approval of its shareholders required to consummate the proposed transaction for the divestiture of UDENYCA; the possibility that competing offers will be made by third parties; the occurrence of any event, change or other circumstance that may give rise to a right of one or both parties to terminate the agreement to divest UDENYCA; the possibility that the proposed transaction for the divestiture of UDENYCA may not be completed in the time frame expected by the Company or at all, including due to the possibility that a governmental entity may prohibit, delay, or refuse to grant approval, if required, for the consummation of the proposed transaction to divest UDENYCA (or only grant approval subject to adverse conditions or limitations). All forward-looking statements contained in this press release speak only as of the date of this press release. Unless required by law, the Company is not under any duty and undertakes no obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, of new information, data or methods, future events or other changes. For a further description of the significant risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Coherus\u2019 business in general, see Coherus\u2019 Quarterly Report on Form 10-Q for the fiscal quarter ended\u00a0September 30, 2024\u00a0filed with the\u00a0Securities and Exchange Commission\u00a0on November 6, 2024, including the section therein captioned \u201cRisk Factors\u201d and in other documents Coherus files with the\u00a0Securities and Exchange Commission including, when available, the proxy statement of the Company relating to the proposed transaction for the divestiture of UDENYCA. UDENYCA \u00ae and LOQTORZI \u00ae , whether or not appearing in large print or with the trademark symbol, are trademarks of Coherus, its affiliates, related companies or its licensors or joint venture partners unless otherwise noted. Trademarks and trade names of other companies appearing in this press release are, to the knowledge of Coherus, the property of their respective owners. Coherus Contact Information: For Investors: Jodi Sievers VP, Investor Relations & Corporate Communications IR@coherus.com For Media: Argot Partners (212) 600-1902 coherus@argotpartners.com 1 Project Optimus: Reforming the dose optimization and dose selection paradigm in oncology 2 Shanghai Junshi Biosciences Co., Ltd (2024, June 11) Junshi Biosciences Announces Phase 3 Study of Toripalimab Combined with Bevacizumab for the First-line Treatment of Advanced Hepatocellular Carcinoma Meets Primary Endpoint 3 FAN, J. (2024) HEPATORCH: A randomized, open-label, multicenter, phase III clinical study of the safety and efficacy of toripalimab combined with bevacizumab vers us sorafenib as first-line treatment for advanced hepatocellular carcinoma presented at the 2024 Annual Meeting of Chinese Society of Clinical Oncology 4 National Cancer Institute Cancer Stat Facts: Liver and Intrahepatic Bile Duct Cancer; retrieved December 17, 2024, from https://seer.cancer.gov/statfacts/html/livibd.html View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CHRS", "date": "2024-12-18T16:30:00", "sentiment": {"score": 0.5162024656310678, "confidence": 0.5247998833656311, "probabilities": {"positive": 0.5247998833656311, "negative": 0.00859741773456335, "neutral": 0.46660271286964417}}, "embedding": [-0.039332613348960876, -0.06746344268321991, -0.07997379451990128, -0.04926907271146774, 0.082011878490448, -0.06505651772022247, -0.17262566089630127, 0.18832817673683167, 0.04356202110648155, 0.094467394053936, -0.0845419391989708, -0.047126203775405884, 0.03488440066576004, 0.07097259163856506, -0.02827754244208336, 0.07784060388803482, 0.03179600462317467, 0.07422508299350739, -0.026265881955623627, 0.03794880956411362, -0.03099304810166359, -0.06615688651800156, 0.048288702964782715, 0.058975838124752045, 0.007589919958263636, -0.01358073204755783, -0.08233705163002014, 0.037835657596588135, -0.22540558874607086, -0.044012006372213364, 0.03853681683540344, 0.0013030730187892914, -0.06269817799329758, 0.02967359870672226, -0.08018431067466736, -0.09968740493059158, -0.049508221447467804, 0.056742727756500244, -0.04879729449748993, -0.07572276145219803, -0.1004033237695694, 0.05984966829419136, -0.020662765949964523, -0.06789779663085938, 0.010497121140360832, -0.22244024276733398, -0.14586642384529114, 0.015838665887713432, 0.09785602986812592, 0.16978541016578674, -0.09337984025478363, 0.05160136520862579, -0.07708148658275604, 0.20690800249576569, -0.048706911504268646, -0.07652604579925537, -0.1326560080051422, -0.05197295546531677, 0.09471595287322998, -0.027855440974235535, -0.057179518043994904, -0.11631731688976288, 0.07523319125175476, 0.09075333178043365, 0.07551701366901398, -0.03941008821129799, -0.08979879319667816, -0.013452108949422836, -0.07323067635297775, 0.022569630295038223, 0.004458660259842873, 0.04025702923536301, 0.10903630405664444, 0.008241548202931881, 0.012338506057858467, 0.14009124040603638, 0.12689146399497986, 0.15601277351379395, 0.15399399399757385, -0.16826346516609192, 0.03245588764548302, 0.15860769152641296, 0.10260933637619019, -0.07232925295829773, -0.028007252141833305, 0.06140866130590439, 0.008189141750335693, 0.20701713860034943, 0.049605775624513626, 0.036475978791713715, 0.1721685379743576, 0.11961159110069275, 0.056843407452106476, 0.06619460880756378, -0.001741599291563034, -0.10554622113704681, 0.07702881842851639, 0.11292040348052979, 0.013921056874096394, -0.04128992184996605, 0.04958482086658478, -0.04210422560572624, -0.00625492911785841, -0.07709521055221558, 0.041078146547079086, 0.02343643642961979, -0.010855719447135925, 0.04960288852453232, 0.08305985480546951, 0.08283136785030365, -0.03718017786741257, -0.0677664577960968, 0.019069721922278404, -0.12106667459011078, 0.014367213472723961, 0.3195955157279968, -0.04889889806509018, 0.029758939519524574, 0.20392638444900513, -0.06158670037984848, 0.08293187618255615, -0.12158308923244476, -0.012952843680977821, -0.15782959759235382, 0.16062583029270172, 0.19037878513336182, -0.01312697771936655, 9.277139537275715e-33, 0.06717624515295029, 0.05292961001396179, 0.15732207894325256, 0.11805205047130585, 0.029907170683145523, -0.05536428093910217, 0.04580659419298172, 0.021499356254935265, -0.14565163850784302, -0.029444947838783264, -0.049539998173713684, 0.13005582988262177, -0.0018852634821087122, 0.09579183161258698, -0.11870305240154266, -0.05820146203041077, -0.04341781884431839, -0.04704398661851883, -0.12357868254184723, -0.09040189534425735, 0.032607030123472214, 0.011646583676338196, -0.13245728611946106, -0.07230617105960846, 0.012570472434163094, 0.024096352979540825, -0.04224970564246178, 0.18130525946617126, -0.09912142157554626, 0.06522304564714432, -0.2761562466621399, -0.00557877030223608, 0.010063446126878262, 0.07456998527050018, -0.05007665976881981, -0.09331420063972473, -0.009975245222449303, -0.11812631785869598, -0.00842089019715786, 0.016373582184314728, 0.09441794455051422, -0.09904538840055466, -0.1242123395204544, -0.10607579350471497, 0.08629929274320602, -0.2266664206981659, -0.1130412369966507, -0.031141508370637894, -0.0628427192568779, 0.08707389235496521, 0.017406631261110306, -0.06645374000072479, -0.04700243100523949, 0.10360968112945557, -0.03692895174026489, 0.0570724681019783, -0.16210219264030457, 0.03157372400164604, 0.13541972637176514, 0.09404873847961426, 0.049506980925798416, -0.008245812729001045, -0.024416916072368622, 0.16683579981327057, -0.027222810313105583, -0.000560760498046875, -0.08807313442230225, -0.004811831749975681, -0.0733439102768898, 0.09908970445394516, -0.08862130343914032, -0.023346465080976486, 0.06442739814519882, 0.07041061669588089, 0.09253767132759094, -0.02536826580762863, 0.09986402094364166, 0.06318304687738419, -0.008910645730793476, 0.07292362302541733, -0.04599037021398544, -0.012924300506711006, -0.25658801198005676, 0.15829229354858398, -0.05853745713829994, -0.051929324865341187, 0.010368170216679573, -0.11274585872888565, -0.26457151770591736, -0.012180725112557411, 0.12687775492668152, -0.07173246145248413, -0.0595930740237236, 0.09155447781085968, 0.027888158336281776, -1.3145030230259525e-32, -0.006222658324986696, 0.024171775206923485, -0.0027276533655822277, -0.05944099277257919, -0.09440775215625763, 0.13715820014476776, 0.2062150239944458, -0.1966247260570526, 0.10560748726129532, -0.2509956657886505, 0.05519633740186691, -0.018973659723997116, -0.026308219879865646, -0.06679326295852661, -0.056606799364089966, -0.018001563847064972, -0.047874365001916885, 0.047200947999954224, -0.1176397055387497, 0.1202675923705101, 0.05682922154664993, 0.12167948484420776, -0.11751767247915268, -0.009298750199377537, -0.08152222633361816, -0.019946841523051262, 0.09338273108005524, 0.008233468979597092, 0.04347292706370354, 0.07959440350532532, 0.06440597027540207, 0.06024794280529022, -0.1964903473854065, -0.03649425879120827, 0.07549165189266205, -0.04681956022977829, 0.06990130990743637, -0.21478155255317688, 0.0201302170753479, -0.027016274631023407, -0.032172828912734985, -0.020192427560687065, -0.1729409098625183, -0.044728852808475494, 0.0568680502474308, 0.08635898679494858, 0.0756106972694397, 0.019158609211444855, 0.11240378767251968, -0.019905032590031624, -0.04545406252145767, -0.034962721168994904, -0.08093249797821045, 0.08041516691446304, -0.08831828087568283, 0.02643171139061451, 0.02629871852695942, -0.019040096551179886, -0.1042073518037796, 0.12376844137907028, -0.019328029826283455, 0.14681661128997803, 0.019087355583906174, -0.053013116121292114, 0.14148253202438354, 0.09981387853622437, -0.021806085482239723, -0.09693758934736252, 0.10785205662250519, -0.09872633963823318, -0.10006304085254669, -0.0591452457010746, -0.08162156492471695, 0.0477021187543869, 0.009376485832035542, 0.050344713032245636, 0.04401702061295509, -0.09183590859174728, -0.0867001861333847, -0.013240484520792961, 0.08147888630628586, -0.06328015774488449, 0.08894722908735275, 0.027364403009414673, 0.031213324517011642, 0.10918493568897247, -0.0518767312169075, -0.0658649131655693, -0.011114832013845444, 0.12856218218803406, -0.02343503199517727, -0.005619929172098637, -0.096172034740448, 0.14150866866111755, -0.12771408259868622, -1.0082257517751714e-07, 0.10448624193668365, -0.05394097790122032, 0.05701145529747009, -0.2595653533935547, -0.08025005459785461, 0.054581545293331146, -0.08056201040744781, -0.12402547895908356, -0.042971402406692505, 0.10702905058860779, 0.13867053389549255, 0.13433223962783813, -0.06518939882516861, 0.010777239687740803, -0.06259758770465851, 0.055552925914525986, -0.009843624196946621, -0.027588151395320892, -0.035531796514987946, 0.017698315903544426, -0.0620708242058754, -0.11886931955814362, 0.016391266137361526, -0.16327790915966034, 0.10893681645393372, -0.0723983645439148, 0.06381715089082718, 0.15842874348163605, 0.04687109217047691, 0.005916043184697628, -0.13952600955963135, -0.10362544655799866, -0.05326192080974579, -0.010727496817708015, 0.06381741166114807, 0.04149541258811951, 0.025874456390738487, -0.05265580117702484, -0.009120813570916653, 0.021659430116415024, 0.1954309046268463, 0.005798048339784145, -0.11570911109447479, -0.10174714028835297, 0.056580353528261185, 0.015622378326952457, -0.1466790735721588, 0.06409673392772675, -0.01639326475560665, -0.04866652190685272, -0.25528866052627563, 0.008558210916817188, -0.058680251240730286, -0.0473531149327755, 0.05149685963988304, 0.02666548080742359, -0.09832490980625153, -0.0003121495246887207, 0.10493645071983337, -0.13439451158046722, 0.10085083544254303, -0.0030816844664514065, 0.039922118186950684, -0.009493693709373474], "changes": {"1wk": -6.369428057385982, "1mo": -9.554145882553037}}, {"text": "Coherus BioSciences (CHRS) Reports Q3 Loss, Tops Revenue Estimates Zacks Equity Research Thu, Nov 7, 2024, 1:15 AM 3 min read In This Article: CHRS Coherus BioSciences (CHRS) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.27 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 90%. A quarter ago, it was expected that this drug developer would post a loss of $0.21 per share when it actually produced a loss of $0.14, delivering a surprise of 33.33%. Over the last four quarters, the company has surpassed consensus EPS estimates two times. Coherus BioSciences , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $70.77 million for the quarter ended September 2024, surpassing the Zacks Consensus Estimate by 24.44%. This compares to year-ago revenues of $74.57 million. The company has topped consensus revenue estimates two times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Coherus BioSciences shares have lost about 78.1% since the beginning of the year versus the S&P 500's gain of 21.2%. What's Next for Coherus BioSciences? While Coherus BioSciences has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Coherus BioSciences: unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.15 on $61.68 million in revenues for the coming quarter and -$0.71 on $264.28 million in revenues for the current fiscal year. Story Continues Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 38% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. TScan Therapeutics, Inc. (TCRX), another stock in the same industry, has yet to report results for the quarter ended September 2024. This company is expected to post quarterly loss of $0.28 per share in its upcoming report, which represents a year-over-year change of -16.7%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. TScan Therapeutics, Inc.'s revenues are expected to be $2.86 million, down 26.4% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Coherus BioSciences, Inc. (CHRS) : Free Stock Analysis Report TScan Therapeutics, Inc. (TCRX) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CHRS", "date": "2024-11-07T01:15:14", "sentiment": {"score": -0.3662555441260338, "confidence": 0.46947282552719116, "probabilities": {"positive": 0.10321728140115738, "negative": 0.46947282552719116, "neutral": 0.42730990052223206}}, "embedding": [-0.09574723243713379, 0.018422633409500122, -0.06623794138431549, 0.07538874447345734, 0.016651129350066185, -0.02255210280418396, -0.13763248920440674, 0.1179969534277916, 0.1979755014181137, 0.11788571625947952, -0.11880004405975342, -0.0110088512301445, -0.04369215667247772, -0.009965449571609497, -0.21449542045593262, -0.051699474453926086, -0.034152284264564514, -0.10013028979301453, -0.08273021131753922, 0.022923458367586136, -0.07612127810716629, 0.10290101915597916, 0.05183056741952896, 0.09383444488048553, 0.09636738151311874, -0.01867697574198246, -0.10804357379674911, -0.06739526987075806, -0.12613816559314728, -0.08512869477272034, -0.004332349635660648, 0.14133310317993164, 0.08792607486248016, -0.05774964392185211, -0.08205609023571014, -0.04496226832270622, 0.023339536041021347, -0.037581175565719604, 0.17939338088035583, 0.14212214946746826, -0.06500788778066635, 0.01905403658747673, -0.21784231066703796, 0.02606367878615856, -0.13218902051448822, -0.1459185779094696, 0.007643762975931168, -0.05402171611785889, 0.011723553761839867, 0.07705534994602203, -0.24976485967636108, -0.1401578187942505, 0.019168758764863014, 0.004652137402445078, -0.08890298008918762, 0.06572402268648148, -0.12497305870056152, -0.061037249863147736, 0.09194371849298477, -0.029070034623146057, 0.1521313339471817, -0.0835975706577301, 0.07715640962123871, 0.11439171433448792, 0.22470465302467346, -0.02966238744556904, 0.009456334635615349, 0.02685006894171238, -0.054191138595342636, 0.01698129251599312, 0.1386251449584961, 0.006534571759402752, -0.0717005729675293, -0.035569511353969574, -0.07956491410732269, 0.20374904572963715, 0.06755873560905457, 0.10913947224617004, 0.14281049370765686, -0.12045350670814514, 0.0620357021689415, -0.033627934753894806, -0.08169309049844742, -0.08652464300394058, 0.04438050836324692, 0.03340534865856171, 0.150408536195755, 0.11816748976707458, -0.041738592088222504, 0.01951805129647255, 0.04133280739188194, -0.18774035573005676, 0.06901071965694427, -0.04864057898521423, -0.06333905458450317, 0.04289238154888153, -0.019263839349150658, -0.10075513273477554, 0.07182653993368149, -0.05601709336042404, 0.07046297192573547, 0.15215425193309784, -0.06169109791517258, -0.12010277807712555, 0.007346215657889843, -0.1639106273651123, 0.07511323690414429, -0.02195511758327484, 0.15235255658626556, 0.1657969355583191, -0.10563184320926666, 0.19155898690223694, -0.16924430429935455, -0.0402083694934845, -0.006905482150614262, 0.1765306293964386, -0.0268696416169405, 0.12465981394052505, 0.1589888036251068, 0.08633109927177429, 0.10168610513210297, 0.03770476579666138, -0.048093922436237335, -0.08219383656978607, 0.032530322670936584, 0.05714889615774155, -0.17454993724822998, 8.53327716118377e-33, 0.10488452017307281, 0.158619225025177, 0.005107387900352478, -0.11234297603368759, -0.030524468049407005, -0.05446094274520874, 0.003285498358309269, -0.06273554265499115, 0.030070170760154724, -0.15411418676376343, -0.22450906038284302, 0.2001708745956421, 0.00773969292640686, -0.04381866753101349, -0.0017116265371441841, -0.10541833937168121, -0.15831764042377472, 0.05211751163005829, 0.00978604331612587, -0.01264894101768732, 0.010198374278843403, 0.032595209777355194, -0.09326416254043579, 0.10412600636482239, 0.03392209857702255, -0.046486176550388336, -0.09820939600467682, 0.044372957199811935, -0.11436668783426285, 0.038573116064071655, -0.0223604217171669, 0.019541295245289803, 0.043417155742645264, -0.13256405293941498, -0.09174259006977081, -0.09229622036218643, -0.03969109058380127, -0.09513973444700241, 0.15304404497146606, 0.025833848863840103, -0.04881957918405533, 0.06490390002727509, -0.08222654461860657, -0.2186741977930069, -0.015196701511740685, 0.01588824763894081, -0.046080950647592545, 0.0006642881780862808, -0.06237472593784332, -0.08184516429901123, -0.1307383030653, 0.04910337179899216, 0.05118102207779884, -0.036607276648283005, 0.010085786692798138, -0.00827653706073761, -0.06612300872802734, -0.27453863620758057, 0.024531356990337372, 0.1136673241853714, 0.12443231046199799, 0.31099045276641846, 0.09556331485509872, 0.028672674670815468, -0.21043851971626282, 0.18592993915081024, 0.007739294320344925, 0.08142253011465073, -0.12343756854534149, 0.2495424449443817, -0.0374857597053051, -0.06536583602428436, 0.04465094208717346, -0.10748794674873352, 0.14482173323631287, -0.0450204461812973, -0.0029276330024003983, -0.06689107418060303, 0.06333769857883453, 0.02640056423842907, 0.10767301917076111, -0.03936871141195297, 0.021551024168729782, -0.04663355275988579, 0.06896395981311798, 0.020243199542164803, 0.027020545676350594, 0.06410153210163116, 0.02855474129319191, 0.02994515374302864, 0.05723056197166443, -0.11021140217781067, -0.004028329160064459, 0.07108977437019348, -0.10192791372537613, -9.508335766195442e-33, -0.14171317219734192, 0.031088408082723618, 0.0008256100118160248, -0.012362221255898476, -0.0892578735947609, 0.01855524443089962, 0.08487860858440399, 0.03669935464859009, 0.01214325800538063, -0.17463640868663788, 0.03207778185606003, 0.08306489139795303, -0.11986251175403595, 0.06408378481864929, -0.051650311797857285, 0.04428169131278992, 0.019449753686785698, -0.11110344529151917, 0.016952689737081528, -0.053258247673511505, 0.03568597882986069, 0.18188558518886566, -0.1527327448129654, 0.07775057852268219, 0.06124504655599594, 0.09119057655334473, 0.04495668411254883, 0.13322925567626953, 0.04030649736523628, -0.07203178107738495, 1.8203631043434143e-05, -0.10312888026237488, -0.20013050734996796, 0.11363580822944641, 0.014053817838430405, -0.024576999247074127, -0.03110884130001068, -0.1046038269996643, 0.009952651336789131, -0.0955304428935051, 0.1762598752975464, 0.05637980252504349, 0.0073744021356105804, 0.01497805304825306, 0.09804591536521912, -0.06205958500504494, -0.0148701723664999, -0.012674044817686081, 0.18858443200588226, 0.14613229036331177, 0.0118289515376091, 0.04402606934309006, -0.08970998227596283, 0.15291735529899597, -0.11179518699645996, 0.06999073922634125, -0.11431615799665451, 0.012276731431484222, -0.12374487519264221, 0.045882925391197205, -0.032627470791339874, 0.15959355235099792, -0.01855374500155449, 0.10662588477134705, 0.040852148085832596, 0.037007033824920654, -0.02240627631545067, 0.06250861287117004, -0.013875003904104233, -0.049306273460388184, 0.09330932796001434, -0.03035990335047245, 0.08784660696983337, -0.167729914188385, -0.010765226557850838, 0.32388296723365784, -0.13403284549713135, -0.20043601095676422, -0.17696069180965424, 0.027750806882977486, 0.03921297937631607, 0.026492750272154808, 0.12689964473247528, -0.005832836963236332, -0.0487818717956543, 0.20068025588989258, -0.003860357217490673, -0.0815671980381012, -0.07721652090549469, -0.04489244893193245, -0.0798407793045044, -0.22920691967010498, -0.12379556894302368, -0.00028561707586050034, 0.12696604430675507, -9.987171267766826e-08, 0.0735839307308197, -0.055314913392066956, 0.11964288353919983, -0.07279296219348907, 0.1721392422914505, -0.08114048838615417, 0.047704387456178665, -0.044639818370342255, 0.0539725162088871, 0.12021579593420029, 0.04939797520637512, -0.012578126974403858, -0.1636681705713272, 0.10721908509731293, -0.08092540502548218, 0.03895333781838417, -0.12290091812610626, 0.09239711612462997, 0.01152871921658516, -0.18708738684654236, -0.07355047762393951, 0.008406981825828552, 0.14155280590057373, -0.03880629688501358, 0.063257597386837, 0.008141768164932728, 0.00857892632484436, -0.007349040359258652, -0.008691085502505302, 0.020216336473822594, 0.061186641454696655, -0.01597379334270954, 0.08893490582704544, 0.08689954876899719, 0.047718897461891174, -0.1467222422361374, 0.06346840411424637, 0.10887215286493301, -0.03298833966255188, 0.1340268850326538, -0.06545408815145493, 0.009752933867275715, -0.02729598432779312, 0.09873342514038086, 0.01661970093846321, -0.12843871116638184, -0.10314576327800751, 0.056864626705646515, 0.06652326136827469, -0.23992954194545746, 0.17550581693649292, -0.08360216021537781, 0.031969811767339706, 0.05214395746588707, 0.07367327809333801, 0.045331522822380066, -0.2045479416847229, -0.01840655691921711, -0.3104373514652252, -0.05578197166323662, 0.12976136803627014, -0.23658624291419983, 0.1235823705792427, 0.10502028465270996], "changes": {"1wk": 7.59668631095316, "1mo": 134.80664384346568}}, {"text": "College Student With $400K In Stocks Grown In Just 4 Years Gets Mixed Reddit Advice \u2013 'Should I Max Out My Roth IRA And Invest In S&P 500?' Paula Tudoran Thu, Dec 19, 2024, 9:00 PM 5 min read In This Article: ^GSPC RDDT Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Many investors have started to seek advice on long-term stock investments and a 23-year-old college student has turned to Reddit to navigate his journey toward financial stability. With a portfolio worth $400K, grown in just four years through individual stocks, the young man aims to invest wisely to purchase a home down the road and secure his retirement fund. With this concern in mind and the fact that he considers day trading a gamble and says he has gotten \u201clucky\u201d so far, the investor asked for long-term stock investment advice on the discussion board, which hosts close to 2.6 million members. Don't Miss: This Jeff Bezos-backed startup will allow you to become a landlord in just 10 minutes, with minimum investments as low as $100 for properties like the Byer House from Stranger Things. Unlock the hidden potential of commercial real estate \u2014 This platform allows individuals to invest in commercial real estate offering a 12% target yield with a bonus 1% return boost today! \u201cI\u2019m a 23, college student, I started investing 4 years ago. I invested $50k into Meta during its stock crash at $122 per share. I currently have a little over $400k in stocks. I have only done individual stocks. I want to invest long-term, as I have a wife and two kids,\u201d he said. While the investor sought advice from fellow Redditors on the r/investing_discussion community, he already had a few options he was considering but was looking for direction. The investor mentioned that he created a Roth IRA and is considering investing in VOO\u2019s S&P 500 but would need to max out his Roth IRA. He also had the option to enroll in a 401(k) through his company but was unsure if it was a good idea. So, let\u2019s analyze the recommendations he received from other Redditors and what they think about investing in VOO\u2019s S&P 500. See Also: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing \u2014 you can become an investor for $0.80 per share today. Redditors\u2019 Recommendations for Long-Term Stock Investment VOO\u2019s S&P 500 Several members of the community advised the investor seeking long-term investment guidance on Reddit to invest in VOO\u2019s S&P 500. \u201cLike, I know the S&P 500 is a great choice for a long-term investment because you can monitor the trend based on the revenue of the companies involved in it,\u201d says one Redditor. Story Continues Another user mentioned that VOO is a great index fund to track the S&P 500, while a third Redditor said that an S&P 500 is usually the safe route for many investors. \u201cThe \u201csafe\u201d answer is usually S&P 500 for most of the money,\u201d the Redditor said. Trending: Warren Buffett once said, \"If you don't find a way to make money while you sleep, you will work until you die.\" Here\u2019s how you can earn passive income with just $100. QQQ\u2019s ETFs Several Redditors on the r/investing_discussion thread also recommended QQQ\u2019s ETFs, particularly suggesting the young man seeking advice find a few ETFs and then take a break. \u201cI'd max out the IRA, continue to contribute to the 401(k) and find a few ETFs (VOO, QQQ, VTI ... etc.) then chill,\u201d the Redditor said. Another board member expressed full confidence in QQQ, advising the investor to fully commit to this fund. \u201cIt depends on your goals and level of expertise. You are young. If you want max returns and can handle fluctuations, I\u2019d go QQQ all the way,\u201d the Redditor commented. CHRS CHRS or Coherus Biosciences, Inc., is a specific option that a Redditor mentioned in the thread. CHRS is a commercial-stage pharmaceutical company that develops and sells innovative immunotherapies for cancer. Although the company\u2019s stock price has decreased 22.97% this year, this Redditor, in particular, believes it is worth investing in. Wondering if your investments can get you to a $5,000,000 nest egg? Speak to a financial advisor today. SmartAsset\u2019s free tool matches you up with up to three vetted financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you. Arrived Achieved A Total Return of 34.7% On Their Biggest Sale Yet \u2014 Diversify Your Monthly Income Stream With Fractional Real Estate Arrived allows individuals to invest in shares of rental properties for as little as $100, providing the potential for monthly rental income and long-term appreciation without the hassles of being a landlord . With over $1 million in dividends paid out last quarter and a growing selection of properties across various markets, Arrived offers an attractive alternative for investors seeking to build a diversified real estate portfolio. In October 2024, Arrived sold The Centennial, achieving a total return of 34.7% (11.2% average annual returns) for investors. Arrived aims to continue delivering similar value across our portfolio through careful market selection, attentive property management, and thoughtful timing in sales. Looking for fractional real estate investment opportunities? The Benzinga Real Estate Screener features the latest offerings. This article College Student With $400K In Stocks Grown In Just 4 Years Gets Mixed Reddit Advice \u2013 'Should I Max Out My Roth IRA And Invest In S&P 500?' originally appeared on Benzinga.com \u00a9 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CHRS", "date": "2024-12-19T21:00:14", "sentiment": {"score": 0.055106306448578835, "confidence": 0.0725848451256752, "probabilities": {"positive": 0.0725848451256752, "negative": 0.017478538677096367, "neutral": 0.9099366068840027}}, "embedding": [0.032771818339824677, 0.020529497414827347, -0.10008742660284042, -0.026321064680814743, -0.014530749060213566, -0.017095904797315598, 0.037583354860544205, 0.09004360437393188, -0.04162678122520447, 0.03887553513050079, -0.037027083337306976, 0.1552165448665619, -0.029546156525611877, -0.014553975313901901, -0.010691296309232712, 0.09816326946020126, 0.032190099358558655, 0.05345170572400093, -0.15042445063591003, 0.12225934863090515, -0.004136836156249046, -0.136286199092865, -0.019466206431388855, -0.06960751116275787, 0.10310745239257812, -0.022858811542391777, 0.049170948565006256, 0.10848274827003479, -0.19931620359420776, 0.021400239318609238, 0.14589986205101013, 0.16468574106693268, 0.006025808863341808, -0.06717083603143692, -0.02340192161500454, 0.12783095240592957, -0.10785406082868576, 0.06661443412303925, 0.16207033395767212, -0.023509571328759193, 0.0077329291962087154, -0.0644308552145958, 0.02548951655626297, 0.03892526775598526, 0.008993912488222122, -0.03811592608690262, 0.024499770253896713, -0.02042963169515133, 0.19527113437652588, -0.12300890684127808, -0.1288173943758011, -0.02557368576526642, -0.009588882327079773, -0.08510496467351913, -0.13863424956798553, 0.03269423171877861, -0.11509738862514496, 0.06802383810281754, 0.026613350957632065, -0.0912194773554802, 0.05974343419075012, -0.006920508574694395, 0.05699795484542847, -0.03732660040259361, 0.07793787121772766, -0.008652954362332821, -0.0364493727684021, 0.04968392103910446, 0.01924397423863411, 0.02419985644519329, 0.12979939579963684, 0.008766207844018936, -0.2095969170331955, -0.022976290434598923, -0.002926330082118511, -0.006625266745686531, -0.019066445529460907, 0.07610150426626205, 0.11292576789855957, -0.08580321073532104, 0.16490882635116577, 0.05276723951101303, -0.104622483253479, -0.11034569144248962, -0.12289303541183472, 0.022223133593797684, -0.02703670784831047, 0.04719468206167221, 0.19208255410194397, 0.04868404567241669, 0.0675123780965805, -0.012597227469086647, 0.020045006647706032, -0.04905985668301582, 0.07523591071367264, 0.05635536462068558, -0.10282167792320251, -0.06771160662174225, -0.16923631727695465, 0.06376631557941437, 0.07425332069396973, -0.015374954789876938, -0.049831751734018326, -0.15695372223854065, 0.007543626241385937, -0.05652538686990738, 0.08149006217718124, 0.07521048933267593, 0.03383549302816391, -0.036761343479156494, -0.07553708553314209, 0.14442817866802216, 0.0021220818161964417, -0.033324338495731354, 0.04701727256178856, 0.13954918086528778, -0.04052384942770004, -0.033596694469451904, 0.12444606423377991, 0.1019507497549057, 0.1247713565826416, 0.10720392316579819, -0.0026299776509404182, -0.015485995449125767, 0.07017815113067627, -0.17686781287193298, -0.13106626272201538, 1.2023207482127845e-32, -0.025836054235696793, 0.2226754128932953, -0.037266094237565994, 0.08357681334018707, -0.02198256365954876, 0.026860682293772697, 0.1336785852909088, -0.00037476979196071625, -0.2153274565935135, -0.04342123866081238, 0.06215823441743851, 0.0788082480430603, -0.057349562644958496, 0.0017976248636841774, 0.04976044222712517, -0.03354116529226303, -0.0962885320186615, 0.04350127652287483, -0.0016376953572034836, -0.13751856982707977, 0.10983099788427353, 0.007621146738529205, 0.0041948542930185795, -0.0287956353276968, 0.056686997413635254, -0.21677514910697937, -0.006467181257903576, -0.030162137001752853, -0.01606871746480465, 0.05637490749359131, -0.08701779693365097, 0.14323782920837402, -0.12621216475963593, -0.10828061401844025, -0.030609123408794403, -0.06125325337052345, -0.08953232318162918, -0.08001160621643066, -0.10651823878288269, -0.009636363945901394, -0.21292123198509216, 0.15179443359375, -0.030818061903119087, 0.06631278991699219, -0.14052274823188782, 0.06716059148311615, 0.03470824658870697, 0.13542057573795319, -0.07951779663562775, 0.03717417269945145, -0.05097624287009239, -0.10261867940425873, -0.050948649644851685, -0.04209616035223007, -0.12874658405780792, -0.003708659205585718, 0.017529288306832314, -0.06315901130437851, -0.09787840396165848, 0.05818425863981247, 0.06276148557662964, 0.028345108032226562, -0.09449885785579681, 0.1485843062400818, -0.17268618941307068, 0.036876335740089417, -0.046250224113464355, 0.1373412013053894, 0.09614554047584534, 0.08293348550796509, 0.10794423520565033, -0.05074518173933029, 0.14552651345729828, -0.19125336408615112, 0.0026655299589037895, -0.0848548412322998, 0.006044892594218254, 0.1393454223871231, -0.0025205619167536497, 0.0005009295418858528, 0.24814945459365845, -0.020401159301400185, -0.060326918959617615, -0.011136405169963837, -0.03644249215722084, 0.12671275436878204, 0.15311332046985626, -0.07990415394306183, -0.004027625545859337, 0.019065579399466515, 0.10447460412979126, -0.06844107061624527, 0.03585324436426163, -0.031197234988212585, -0.03300321847200394, -1.0317625423170185e-32, -0.08678007870912552, -0.011264875531196594, 0.07785822451114655, -0.05807830020785332, 0.0784614086151123, 0.06021510809659958, 0.05039682239294052, -0.08079805225133896, -0.04204273223876953, -0.09540397673845291, -0.027660343796014786, 0.010055764578282833, 0.01662631519138813, 0.026026515290141106, -0.11113156378269196, -0.13709372282028198, -0.041802600026130676, -0.10472923517227173, 0.004577708430588245, -0.07759904116392136, 0.05800621956586838, 0.133497953414917, -0.08709694445133209, 0.12119920551776886, -0.01225899625569582, 0.03710264712572098, -0.10211306065320969, 0.32299691438674927, -0.030418097972869873, 0.08265632390975952, -0.04461998492479324, 0.03421638906002045, -0.12431036680936813, -9.25157219171524e-05, -0.04311997815966606, 0.000635126605629921, 0.03483451530337334, -0.017172658815979958, -0.11329656839370728, 0.04685664921998978, 0.19121330976486206, -0.07353610545396805, -0.0035269837826490402, -0.09071033447980881, 0.021024005487561226, -0.013714499771595001, 0.06120836362242699, -0.03792988508939743, 0.17440134286880493, -0.006863625720143318, 0.05551837012171745, 0.014092033728957176, -0.023216664791107178, 0.10112922638654709, 0.03011513315141201, -0.015884865075349808, 0.053302519023418427, 0.03283002972602844, -0.07295975089073181, 0.10209797322750092, -0.0967438668012619, 0.1527896225452423, 0.025134488940238953, 0.0708870142698288, 0.04473947361111641, -0.078553207218647, -0.04251284897327423, -0.11185391992330551, -0.06752564758062363, -0.10593898594379425, -0.12238626182079315, -0.08796947449445724, 0.11825942248106003, -0.159948468208313, -0.006800135597586632, 0.20777645707130432, 0.050239358097314835, 0.010064495727419853, -0.015428092330694199, 0.04395104944705963, -0.0904015600681305, -0.03967219591140747, -0.04981038719415665, 0.05120610445737839, 0.021709907799959183, -0.06897315382957458, -0.12828049063682556, -0.06817717850208282, 0.04320739954710007, 0.004119768273085356, -0.0005545113235712051, -0.05723172798752785, 0.09996042400598526, -0.021240543574094772, 0.04385911673307419, -9.964473690615705e-08, -0.02358907274901867, 0.05379587039351463, -0.03945937007665634, -0.02320486679673195, 0.06669709831476212, -0.010259333997964859, 0.11282408237457275, -0.045263707637786865, 0.08669885993003845, 0.08067888021469116, 0.14182378351688385, 0.026895321905612946, -0.02304127812385559, 0.045329026877880096, -0.13891789317131042, -0.16430526971817017, -0.07269784063100815, -0.038706738501787186, -0.06693589687347412, 0.08061715960502625, 0.22264084219932556, -0.060900501906871796, -0.018222998827695847, 0.033202819526195526, -0.016084210947155952, -0.003117077052593231, 0.029964368790388107, 0.11835439503192902, -0.0033015746157616377, 0.10792946815490723, -0.031134571880102158, -0.10551366209983826, 0.008118277415633202, 0.0536578893661499, -0.08195416629314423, -0.038315121084451675, 0.051951222121715546, 0.08827689290046692, 0.030828451737761497, 0.04759044200181961, 0.04243171960115433, -0.20960737764835358, 0.009381484240293503, -0.07050728052854538, 0.03497745096683502, -0.01572779193520546, -0.11790283769369125, -0.01751570776104927, 0.18414553999900818, -0.09343166649341583, 0.03792252391576767, -0.01658712327480316, 0.008047962561249733, 0.0018691066652536392, 0.12463538348674774, -0.06420940905809402, -0.09688408672809601, 0.05706218257546425, -0.12248630821704865, -0.006951069459319115, 0.056482721120119095, -0.10276586562395096, -0.13300791382789612, 0.1360929310321808], "changes": {"1wk": 0.6756750225933819, "1mo": -6.08108325802206}}, {"text": "Coherus BioSciences Inc (CHRS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ... GuruFocus News Thu, Nov 7, 2024, 10:26 AM 4 min read In This Article: CHRS Total Net Product Revenue: $70.6 million, a 21% increase over Q2. Net Revenue: $66 million, a 30% increase quarter over quarter and a 100% increase over Q3 2023. Icca Revenue: $66 million, 100% growth since Q3 2023. Icca Market Share: Nearly 30% share, maintaining the number two position. Lact Sales: $5.8 million in Q3, a 54% increase quarter over quarter. Cost of Goods Sold: $20.7 million, down $12 million from Q3 last year. Gross Profit Improvement: 20% improvement or $8.2 million. R&D Expense: $21.7 million, a decrease of 15% from Q3 a year ago. SG&A Expense: $34.7 million, a decrease of 28% compared to the prior year. Interest Expense: $5.4 million, a decrease of 48% from Q3 last year. Net Loss: $10.8 million or 9 per diluted share. Non-GAAP Net Loss: $1.7 million or 1 per diluted share. Cash and Investments: $97.7 million as of September 30, 2024. 2024 Expense Guidance: Combined R&D and SG&A expenses expected to be $250 million to $260 million. Warning! GuruFocus has detected 5 Warning Signs with CHRS. Release Date: November 06, 2024 For the complete transcript of the earnings call, please refer to the full earnings call transcript . Positive Points Coherus BioSciences Inc ( NASDAQ:CHRS ) reported a 100% revenue growth for the Icca franchise since Q3 2023, reaching $66 million in revenue this quarter. The company successfully maintained its number two market position for Icca with nearly 30% market share. Coherus BioSciences Inc ( NASDAQ:CHRS ) achieved a 54% increase in sales for its newly launched product, Latur, quarter over quarter. The company has made significant progress in expanding its supply chain capacity, with plans to double its labeling and packaging capacity to over 1 million units annually. Coherus BioSciences Inc ( NASDAQ:CHRS ) reported a 20% improvement in quarterly gross profit compared to the previous year, driven by reduced expenditures and improved gross margins. Negative Points There was a supply interruption for Icca, which impacted the company's ability to meet demand and affected Q4 sales projections. The resupply of Icca is expected to take several weeks, with full market availability anticipated by late November to early December. The company faced a temporary decline in overall franchise demand for Icca by 3% quarter over quarter due to the supply interruption. Coherus BioSciences Inc ( NASDAQ:CHRS ) experienced a net loss of $10.8 million in Q3 2024, although this was an improvement from the previous year. The direct impact of the temporary supply interruption on net revenue will primarily be realized in Q4 earnings, with cash impact lagging to Q1 2025. Story Continues Q & A Highlights Q : Can you provide expectations for the KDO and Tori trial in second-line lung cancer, given some recent competitive challenges? A : Dennis Lanfear, CEO, and Rash Dias, Chief Medical Officer, explained that they are building on promising data, including rare monotherapy partial responses in PD-L1 refractory subjects. The bar for second-line treatment is low, with standard care being docetaxel alone, which has a low response rate. They plan to proceed with a phase three study if results are favorable. Q : When will ICCA be available in the commercial channel again, and how have accounts managed without it? A : Paul Reider, Chief Commercial Officer, stated that sales are expected to resume in late November to early December. Some accounts managed with existing stock, while others switched to alternative products. Many customers have assured they will return to ICCA once available. Q : What is the expected response rate for the CZ Dozo trial in late-line lung cancer, and what benchmarks are you using? A : Rash Dias, Chief Medical Officer, noted that the baseline response rate for docetaxel is around 12%. They are looking for an increment over this in their trial, which follows a standard Simon two-stage design. Q : At what point do you expect to meet all demand for ICCA in the marketplace? A : Dennis Lanfear, CEO, mentioned that they plan to produce 120,000 units in five weeks, which should meet several months' demand. They expect to have all products in the market within three to five weeks. Q : Will there be an even restocking of ICCA formulations, or is there a priority? A : Paul Reider, Chief Commercial Officer, indicated that restocking will follow a sequential flow, starting with the on-body device, followed by pre-filled syringe and auto-injector. Once initial restocking is complete, all formulations will be available in the channel. For the complete transcript of the earnings call, please refer to the full earnings call transcript . This article first appeared on GuruFocus . View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CHRS", "date": "2024-11-07T10:26:32", "sentiment": {"score": 0.8012172132730484, "confidence": 0.8817998766899109, "probabilities": {"positive": 0.8817998766899109, "negative": 0.08058266341686249, "neutral": 0.03761744871735573}}, "embedding": [-0.05977575108408928, -0.08001790940761566, -0.0916934534907341, -0.023217910900712013, -0.004601794295012951, -0.0016201119869947433, -0.10669410228729248, 0.1440824419260025, 0.16156646609306335, 0.12235088646411896, 0.0021886108443140984, -0.12665605545043945, 0.0047927722334861755, 0.0534173846244812, -0.07765068858861923, -0.015032123774290085, -0.03196309506893158, -0.13279052078723907, -0.027201998978853226, -0.04066121578216553, 0.016483264043927193, 0.07708080112934113, -0.05048486590385437, -0.0035390458069741726, 0.061439335346221924, -0.030584659427404404, -0.07945418357849121, -0.05204353481531143, -0.08698958903551102, -0.0706438273191452, 0.03499289229512215, 0.10306219756603241, 0.017930595204234123, -0.021911833435297012, 0.005433989688754082, 0.013184823095798492, -0.011404333636164665, -0.0986146628856659, 0.03770262748003006, 0.051235415041446686, -0.05575885623693466, 0.00504991365596652, -0.16422039270401, 0.035379063338041306, -0.02862793579697609, -0.07981052994728088, -0.07494725286960602, 0.01465563289821148, 0.04705163091421127, 0.00825406238436699, -0.1270427703857422, -0.07729115337133408, -0.02207198366522789, -0.005874980241060257, -0.023492999374866486, 0.04721582680940628, -0.08310744911432266, -0.07304267585277557, 0.03046969510614872, -0.07396970689296722, 0.1065039113163948, -0.10942070186138153, 0.09283985197544098, 0.06891396641731262, 0.13863873481750488, -0.012499452568590641, -0.08150923252105713, 0.015156017616391182, -0.021714994683861732, -0.026149418205022812, -0.0411219522356987, -0.06243479996919632, -0.04619154334068298, -0.07850489020347595, -0.0002472563646733761, 0.24923719465732574, 0.095314159989357, 0.04572615772485733, 0.10715290904045105, -0.16330274939537048, 0.023516956716775894, 0.04790225625038147, -0.0682479664683342, -0.02687249518930912, 0.00675547681748867, 0.011558908969163895, 0.14801788330078125, 0.05475682020187378, 0.0011701672337949276, -0.04746586084365845, 0.1396678388118744, -0.07098875194787979, 0.009243940003216267, -0.0706644132733345, -0.13882635533809662, -0.008758911862969398, -0.06660996377468109, -0.053119830787181854, 0.05549914017319679, -0.05138394981622696, 0.06624241173267365, 0.04768989235162735, -0.11146663874387741, -0.08850760757923126, -0.1208934485912323, -0.08602842688560486, 0.05685634911060333, 0.08492886275053024, 0.11753757297992706, 0.07360915839672089, -0.16434264183044434, 0.18569985032081604, -0.11365760862827301, -0.07259224355220795, -0.015902794897556305, 0.274436354637146, -0.023465799167752266, 0.0193006731569767, 0.20363634824752808, -0.007080510258674622, 0.061643704771995544, -0.01972406730055809, -0.05124657601118088, -0.040738217532634735, -0.06395881623029709, -0.008302364498376846, -0.11378762871026993, 1.532787621996248e-32, -0.0018207773100584745, 0.11188079416751862, 0.05168011039495468, -0.17069368064403534, -0.013554787263274193, 0.004326107911765575, 0.04053459316492081, 0.012522776611149311, -0.07812386006116867, -0.09761717915534973, -0.16053369641304016, 0.15323001146316528, -0.07382208853960037, -0.015138523653149605, 0.06341409683227539, -0.09950754046440125, -0.11642386019229889, 0.06551679968833923, -0.016633307561278343, -0.051178209483623505, -0.044683072715997696, -0.007692303508520126, -0.029225939884781837, 0.1332760751247406, 0.12744075059890747, 0.008144902996718884, -0.009939614683389664, 0.07748573273420334, -0.009756757877767086, 0.033044904470443726, -0.03704395890235901, -0.03947852551937103, -0.0247054323554039, -0.10303981602191925, -0.09065677225589752, -0.025784552097320557, -0.07859119772911072, -0.12667366862297058, 0.06902312487363815, -0.013096009381115437, -0.022405147552490234, 0.09933718293905258, -0.025199444964528084, -0.12725690007209778, -0.06814809143543243, 0.02098149061203003, -0.033384472131729126, -0.01511340495198965, -0.028721719980239868, 0.02574930340051651, -0.16043931245803833, 0.04357767477631569, -0.03509548306465149, 0.004630091600120068, 0.03705139458179474, -0.03130876272916794, 0.03072923794388771, -0.16360369324684143, 0.07504560798406601, 0.12712591886520386, -0.030080553144216537, 0.033933766186237335, -0.03252588212490082, 0.03491746261715889, -0.1462864875793457, 0.145432710647583, 0.050278931856155396, 0.04657961055636406, 0.011485587805509567, 0.14994092285633087, -0.0533473864197731, -0.06652668118476868, 0.12570351362228394, -0.044368453323841095, 0.12181216478347778, -0.07285181432962418, -0.0790276825428009, 0.03304778039455414, -0.013446279801428318, 0.026176834478974342, -0.018276670947670937, 0.0769336074590683, 0.046562906354665756, -0.07619604468345642, 0.011347188614308834, -0.020313873887062073, -0.02936379611492157, 0.030096419155597687, -0.05296134576201439, 0.05236957222223282, 0.06145540624856949, 0.015362243168056011, 0.03367017209529877, 0.13176684081554413, -0.13722506165504456, -1.4102267606228762e-32, -0.09275908768177032, 0.038615383207798004, -0.008557145483791828, -0.05378337204456329, -0.0451832190155983, 0.012793205678462982, 0.0649416521191597, 0.02336537092924118, 0.04156281426548958, -0.1339694857597351, 0.060736626386642456, 0.10125549137592316, -0.10569047927856445, 0.0406644344329834, -0.045355118811130524, 0.053450532257556915, 0.019571490585803986, -0.054433584213256836, 0.03497948870062828, 0.025282369926571846, 0.07047737389802933, 0.22230719029903412, -0.07383348792791367, 0.04463547095656395, 0.03348008170723915, 0.12488187849521637, 0.012280557304620743, 0.05189800634980202, 0.018241798505187035, -0.02972683683037758, 0.00368338730186224, -0.06314878165721893, -0.20403099060058594, 0.14737030863761902, 0.007328909821808338, -0.11278119683265686, 0.09267087280750275, -0.09904810041189194, 0.02854403667151928, 0.005689254961907864, 0.16767510771751404, 0.0921231061220169, -0.034036919474601746, 0.019866973161697388, 0.03607548028230667, -0.06942351162433624, 0.07448902726173401, -0.07810699939727783, 0.11902859807014465, 0.12557831406593323, -0.05090314894914627, 0.017344370484352112, -0.031491369009017944, 0.06694161891937256, -0.10000413656234741, 0.12156272679567337, 0.032526567578315735, 0.10050176829099655, -0.07017773389816284, -0.02552175149321556, 0.035460758954286575, 0.13443675637245178, -0.020021257922053337, -0.031221993267536163, 0.0648726299405098, 0.07146421074867249, 0.033862777054309845, 0.013576159253716469, 0.049928441643714905, -0.14743146300315857, -0.008436616510152817, 0.034539368003606796, -0.001954631879925728, -0.16328918933868408, -0.06102662906050682, 0.11719170212745667, -0.08056211471557617, -0.08824268728494644, -0.07314740121364594, -0.006118496879935265, -0.05445088818669319, 0.05577338486909866, 0.14811356365680695, 0.05041460692882538, 0.033951159566640854, 0.05607358366250992, -0.032127104699611664, -0.11145997047424316, -0.07855166494846344, 0.08366066217422485, -0.1464139223098755, -0.03484807163476944, 0.040907979011535645, 0.09603556990623474, 0.08163219690322876, -1.0007430262248818e-07, 0.06237529218196869, -0.02770295739173889, 0.03430705517530441, -0.028155282139778137, 0.13501152396202087, -0.1785956621170044, 0.037198975682258606, 0.06522403657436371, -0.017687402665615082, 0.12123915553092957, 0.043888159096241, -0.01635603792965412, -0.1817401647567749, 0.08292360603809357, -0.050732389092445374, 0.018367405980825424, -0.09319348633289337, 0.08301414549350739, -0.01832902804017067, -0.10748377442359924, 0.016797315329313278, 0.05841098725795746, 0.09612923860549927, 0.013565631583333015, 0.012902711518108845, 0.004487695172429085, 0.08462812006473541, 0.0976877510547638, 0.035021647810935974, -0.01817443035542965, 0.06637056916952133, -0.003286343067884445, 0.08148433268070221, 0.08499475568532944, 0.029780441895127296, -0.12632305920124054, 0.015785636380314827, 0.10116900503635406, 0.036926981061697006, 0.20823827385902405, -0.08097559213638306, 0.00908629409968853, -0.037966929376125336, 0.07832861691713333, 0.06500046700239182, -0.032550208270549774, -0.20188792049884796, -0.05744101107120514, 0.053660791367292404, -0.10083355754613876, 0.08987241238355637, -0.07652432471513748, -0.002003493020310998, -0.0005492893978953362, 0.006785659585148096, -0.04285939782857895, -0.11567823588848114, -0.013997670263051987, -0.1726553589105606, -0.01374442782253027, 0.12749232351779938, -0.29292166233062744, 0.13991253077983856, 0.025836341083049774], "changes": {"1wk": -5.000001090328878, "1mo": 107.3170807941694}}, {"text": "HNO International's Chairman & CEO Releases Exclusive 'Hydrogen Economy Vision' Video Interview from the NASDAQ Marketsite PR Newswire Fri, Dec 20, 2024, 4:00 PM 3 min read In This Article: HNOI HOUSTON , Dec. 20, 2024 /PRNewswire/ -- HNO International, Inc. (OTC: HNOI), a leader in hydrogen-based clean energy technologies, is pleased to announce the release of Donald Owens' , Chairman and CEO of HNO International, 'Hydrogen Economy' vision interview from the NASDAQ Marketsite, Times Square, New York . HNO International, a clean and green hydrogen (PRNewsfoto/HNO International) Watch the full interview with Stock News Reports here: HNO International: Outline of the company's ambitious plans to revolutionize the energy sector The selection of topics covered included: Local Production, Local Consumption Infrastructure Model with SHEP\u2122 Higher Efficiency with Gaseous Hydrogen vs Liquid Hydrogen Franchise Model for Entrepreneurs Hydrogen Refueling and Dispensing Made Simple with CHRS\u2122 Mobile\u00a0Refueler: Hydrogen Delivery Unit for on-demand fueling and flexible deployment Powering Data Centers and Cryptocurrency with Hydrogen The Future of\u00a0HNOI and their Current Products Leading HNO International's mission to revolutionize the energy sector, Mr. Owens brings unparalleled expertise in hydrogen production and combustion technology. Transitioning from his early career as a patent attorney, he has secured 19 patents in the hydrogen energy industry, solidifying HNO International's position as a leader in hydrogen-based clean energy solutions. \"The experience of bringing our company to the NASDAQ floor for an interview has been enlightening and only furthers our commitment to bring our vision to the global markets. Discussing the importance of decentralizing gaseous hydrogen production and empowering entrepreneurs worldwide reaffirms our mission to make hydrogen energy accessible to everyone,\" commented Mr. Owens. About HNO International HNO International (HNOI) is a company specializing in the design, integration, and development of green hydrogen-based energy technologies. With over 15 years of experience in green hydrogen production, HNOI and its leadership team are on a mission to help lead the renewable energy transition by making energy accessible to businesses and communities worldwide. Their pioneering solutions, including the Scalable Hydrogen Energy Platform (SHEP\u2122 ) and the Compact Hydrogen fuel cell system that Refueling Station (CHRS\u2122 ) , are setting new standards for green hydrogen production. Forward-Looking Statements This news release contains \"forward-looking statements\" which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as \"anticipate\", \"seek\", intend\", \"believe\", \"estimate\", \"plan\", or similar phrases may be deemed \"forward-looking statements\" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K, our quarterly reports on Form 10-Q and other periodic reports filed from time to time with the Securities and Exchange Commission. For more information, please visit www.sec.gov . Story Continues Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/hno-internationals-chairman--ceo-releases-exclusive-hydrogen-economy-vision-video-interview-from-the-nasdaq-marketsite-302336873.html SOURCE HNO International View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CHRS", "date": "2024-12-20T16:00:00", "sentiment": {"score": 0.44762389827519655, "confidence": 0.45629167556762695, "probabilities": {"positive": 0.45629167556762695, "negative": 0.0086677772924304, "neutral": 0.535040557384491}}, "embedding": [-0.059819675981998444, 0.06619162857532501, -0.022791540250182152, -0.021111203357577324, 0.12339019775390625, -0.1300647109746933, -0.004856502171605825, 0.055092424154281616, -0.07068641483783722, -0.10535377264022827, -0.06913775950670242, 0.010729152709245682, -0.009019028395414352, -0.05864004045724869, 0.00145011767745018, -0.01717163249850273, 0.07133304327726364, -0.06078796461224556, -0.09689720720052719, -0.09810830652713776, 0.06380622088909149, -0.1728513240814209, 0.06790876388549805, 0.0031192339956760406, -0.04274553805589676, 0.1272362768650055, 0.014167633838951588, 0.13866916298866272, -0.11505520343780518, -0.048963502049446106, -0.021161945536732674, 0.12007107585668564, 0.08950893580913544, -0.06433948874473572, 0.039767660200595856, 0.1607217937707901, -0.07357227802276611, -0.06768623739480972, 0.015963179990649223, -0.014252811670303345, 0.019058719277381897, -0.2545865476131439, -0.08650034666061401, -0.023367268964648247, 0.004673220217227936, -0.11774979531764984, 0.058226678520441055, -0.004567558877170086, -0.04885896295309067, -0.12234508991241455, -0.06794605404138565, -0.08733928203582764, 0.15726134181022644, -0.06126011908054352, -0.005016781389713287, 0.14312316477298737, -0.044363752007484436, 0.0179941114038229, 0.11727309972047806, -0.07124275714159012, -0.0032723909243941307, -0.10789728164672852, 0.04812488704919815, 0.0243527889251709, 0.2073001116514206, -0.0417262427508831, 0.06470812857151031, 0.06059025973081589, 0.010959632694721222, -0.20501671731472015, 0.08143090456724167, -0.06712134927511215, -0.034374333918094635, -0.005454815924167633, -0.08067741990089417, -0.007709515746682882, 0.19937483966350555, 0.05785743147134781, 0.13342955708503723, -0.027335695922374725, 0.14356383681297302, 0.12965989112854004, -0.06608553230762482, -0.12585154175758362, -0.10384461283683777, 0.0749409943819046, -0.04858795180916786, -0.040324680507183075, 0.0004862844944000244, -0.04420783370733261, -0.08354751765727997, -0.013548992574214935, 0.012484302744269371, -0.06310853362083435, 0.09348967671394348, 0.08295551687479019, 0.03514630347490311, 0.03841352462768555, 0.03870116546750069, -0.07678402960300446, 0.08823470026254654, 0.12138959765434265, -0.10380642861127853, -0.08556867390871048, -0.10835100710391998, -0.04554884135723114, -0.05098145455121994, 0.18141458928585052, 0.19179895520210266, 0.025697574019432068, -0.13028891384601593, 0.0015618465840816498, -0.13873951137065887, -0.13789093494415283, -0.13536669313907623, 0.04330035299062729, -0.07684305310249329, -0.04351768642663956, 0.11059676110744476, -0.10428772866725922, -0.03269870951771736, -0.002494804561138153, -0.07124193757772446, -0.09173861145973206, 0.11738374829292297, -0.07095235586166382, -0.16040004789829254, 9.57415316426592e-33, -0.1314646303653717, 0.08126464486122131, 0.030618399381637573, -0.03644927591085434, 0.016699524596333504, 0.07646845281124115, -0.0662764459848404, 0.059023551642894745, 0.007681896910071373, -0.09875819087028503, -0.048617757856845856, 0.06619486212730408, -0.06138591468334198, -0.05849289149045944, -0.11617003381252289, -0.2294791340827942, -0.012718787416815758, 0.05782676488161087, -0.05731851980090141, 0.050940290093421936, -0.008525634184479713, 0.05885986238718033, 0.003557030577212572, -0.0008520819246768951, 0.10473759472370148, 0.023154692724347115, 0.1220705509185791, -0.15599891543388367, 0.15675640106201172, 0.06286918371915817, -0.03561948612332344, 0.10768850147724152, -0.02742418274283409, -0.010814020410180092, -0.1012551411986351, -0.0886639878153801, -0.2196122705936432, -0.08806462585926056, -0.0840376764535904, -0.06294842064380646, -0.13819026947021484, 0.1785084456205368, -0.09675676375627518, -0.010037576779723167, -0.004536726977676153, 0.07227185368537903, 0.1378084272146225, -0.05609140545129776, 0.0703856498003006, -0.07759898155927658, -0.09175986051559448, 0.11098375916481018, 0.05494164675474167, -0.1761549711227417, 0.13810253143310547, -0.04774142801761627, 0.12420506775379181, -0.16773322224617004, 0.0948415994644165, 0.10778670012950897, -0.1980379968881607, 0.24285195767879486, -0.1967742145061493, 0.08115798234939575, -0.027716612443327904, 0.1342698037624359, -0.04991154000163078, 0.02793288417160511, 0.09378931671380997, 0.07927041500806808, 0.11033672094345093, -0.04391676187515259, 0.06506966054439545, 0.019922714680433273, 0.007280816324055195, 0.02469964697957039, 0.019740499556064606, 0.01250807847827673, -0.041340723633766174, -0.056380629539489746, 0.031621601432561874, -0.015359681099653244, 0.19934870302677155, -0.024206874892115593, 0.00649249367415905, -0.053073279559612274, -0.10645844787359238, -0.01864636316895485, 0.08606727421283722, 0.10726658999919891, 0.052510421723127365, -0.1511102318763733, 0.1172843724489212, 0.02289431169629097, 0.008999479934573174, -1.1097582087988097e-32, 0.03228577971458435, 0.02544962242245674, -0.12292583286762238, -0.04733511060476303, 0.10695342719554901, 0.037099439650774, -0.0008055642247200012, -0.07715308666229248, 0.08673540502786636, -0.12241403758525848, -8.330214768648148e-05, -0.06419838219881058, -0.06074608862400055, 0.023402968421578407, 0.020281655713915825, 0.04477010294795036, 0.020082009956240654, -0.09585690498352051, -0.09815943241119385, 0.06247382611036301, 0.043172016739845276, 0.13006089627742767, -0.11114515364170074, 0.1470828652381897, -0.03850638121366501, -0.02058488130569458, 0.10856340825557709, 0.10043074190616608, 0.16090500354766846, -0.023013442754745483, -0.05208754539489746, -0.07977157831192017, -0.13990505039691925, 0.06763504445552826, 0.0691772922873497, 0.010723598301410675, -0.044044025242328644, 0.03938718140125275, 0.0152506735175848, -0.00880768708884716, 0.0848647877573967, -0.1865357756614685, -0.04520529508590698, -0.07847268134355545, -0.2097509205341339, 0.041039276868104935, -0.14265058934688568, -0.11400802433490753, -0.010738637298345566, 0.035653211176395416, -0.010166515596210957, 0.03848917782306671, -0.08314581215381622, -0.029643774032592773, -0.0938589870929718, 0.010216931812465191, 0.05229441821575165, 0.1962401568889618, -0.027064794674515724, 0.02783823385834694, 0.09476099163293839, 0.02873934619128704, 0.10481558740139008, 0.1866956204175949, -0.09567934274673462, -0.025566093623638153, 0.08287782967090607, -0.1543942093849182, 0.034816160798072815, -0.16035735607147217, -0.06717647612094879, -0.08208256959915161, 0.0690767839550972, 0.00966738723218441, -0.0533132366836071, -0.0009754644706845284, -0.03442899137735367, -0.17589071393013, -0.037536509335041046, -0.05622485280036926, -0.03131457418203354, 0.08049709349870682, -0.04808630794286728, -0.02786567248404026, 0.19817055761814117, -0.040177833288908005, 0.01852007582783699, -0.06548138707876205, 0.0057814717292785645, 0.07206711173057556, 0.0957602709531784, -0.04499620944261551, -0.20298941433429718, 0.1551743447780609, -0.03500819578766823, -1.0103710224029783e-07, -0.0047646863386034966, -0.13922852277755737, 0.12030655145645142, 0.059796836227178574, 0.06719712167978287, -0.04914696142077446, 0.0836348682641983, 0.01687132753431797, 0.11277715861797333, 0.15713593363761902, 0.1126067265868187, 0.02237509936094284, -0.009791018441319466, -0.13948902487754822, 0.026962198317050934, -0.04057995229959488, 0.010185719467699528, 0.04542677477002144, -0.043787240982055664, 0.02423718385398388, -0.008404415100812912, 0.001366020180284977, -0.09377129375934601, 0.021356411278247833, 0.11723915487527847, -0.050438232719898224, 0.06551357358694077, 0.04378104209899902, 0.06736988574266434, -0.1315937638282776, 0.002874061930924654, 0.040048543363809586, 0.07920538634061813, 0.05939207971096039, 0.046481795608997345, -0.022473759949207306, 0.10165508836507797, 0.06588464230298996, -0.08133038878440857, -0.019458787515759468, -0.03954674303531647, 0.07496751099824905, -0.015716159716248512, -0.019381484016776085, -0.02376824989914894, -0.04808604344725609, -0.2742668390274048, 0.021543461829423904, 0.08938434720039368, 0.07941189408302307, -0.07368948310613632, -0.04856393486261368, 0.04353298246860504, 0.0340852364897728, 0.17326581478118896, 0.02078014798462391, -0.050310201942920685, -0.06256698071956635, -0.012072994373738766, 0.06287588179111481, 0.23133611679077148, -0.08670653402805328, 0.1472967267036438, 0.11897532641887665], "changes": {"1wk": -1.9736823530408252, "1mo": -8.552631372560091}}, {"text": "RDY Launches Loqtorzi Biosimilar in India for Nasopharyngeal Carcinoma Zacks Equity Research Fri, Nov 29, 2024, 6:09 PM 3 min read In This Article: PFE Dr. Reddy\u2019s Laboratories RDY announced that it has launched a biosimilar of Coherus BioSciences \u2019 CHRS Loqtorzi (toripalimab) in India under the brand name Zytorvi for the treatment of adults with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC), a rare form of head and neck cancer. Loqtorzi, a novel anti-PD-1 monoclonal antibody, is a new biological entity that has been developed by Coherus in collaboration with China-based Junshi Biosciences. In October 2023, CHRS announced the FDA\u2019s approval of Loqtorzi in combination with cisplatin gemcitabine for the first-line treatment of adults with RM-NPC. The drug was also approved as a monotherapy for treating adults with recurrent unresectable, or metastatic NPC with disease progression on or after platinum-containing chemotherapy. Loqtorzi is the first and only FDA-approved immuno-oncology drug for this carcinoma indication. Consequently, Coherus launched Loqtorzi in the U.S. market in early 2024. The drug is also currently approved in other geographies, including the EU and the U.K. for treating the RM-NPC indication. Coherus as well as its partners plan to further evaluate Loqtorzi in multiple clinical studies for various other oncology indications. Year to date, shares of Dr. Reddy\u2019s have gained 1.2% compared with the industry\u2019s 11.6% growth. Zacks Investment Research Image Source: Zacks Investment Research RDY\u2019s Strategic Collaboration to Market Toripalimab in India In 2023, Dr. Reddy\u2019s signed a licensing and commercialization agreement with Junshi Biosciences for Toripalimab. Through this partnership, Dr. Reddy\u2019s secured exclusive rights to develop and market Toripalimab in 21 countries, including India, South Africa, Brazil and several Latin American nations. The agreement also includes provisions to expand the scope of the license to additional regions, such as Australia, New Zealand and nine other countries. With RDY\u2019s launch of the Loqtorzi biosimilar in India, it became the third country globally, after China and the United States, to gain access to this next-generation PD-1 inhibitor. Patients suffering from NPC face poor prognosis in advanced stages. India is among the top five countries in the world in terms of disease burden for this indication. GLOBOCAN 2022 reported more than 120,000 newly diagnosed NPC cases worldwide in 2022. In India, 6,519 new cases were recorded, with the highest age-adjusted incidence rates observed in the northeastern states. Kohima, Nagaland, reported the highest incidence at 19.4 cases per 100,000 population. Toripalimab, in earlier clinical studies, has demonstrated superior outcomes for RM-NPC compared to the standard-of-care chemotherapy (gemcitabine and cisplatin), thereby meeting a significant unmet need for patients with NPC in India. The combo regimen of toripalimab and standard-of-care chemotherapy has demonstrated a 48% reduction in risk of progression or death in RM-NPC patients. Story Continues Dr. Reddy's Laboratories Ltd Price and Consensus Dr. Reddy's Laboratories Ltd price-consensus-chart | Dr. Reddy's Laboratories Ltd Quote RDY\u2019s Zacks Rank & Other Stocks to Consider Dr. Reddy\u2019s currently carries a Zacks Rank #2 (Buy). Some other top-ranked pharma stocks are Pfizer PFE and Gilead Sciences GILD, each carrying a Zacks Rank #2 at present.\u00a0You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here . Over the past 60 days, Pfizer\u2019s earnings estimates have risen from $2.62 to $2.91 per share for 2024, while that for 2025 has increased from $2.84 to $2.91. PFE shares have lost 10.3% year to date. Pfizer\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 74.50%. Over the past 60 days, Gilead Sciences\u2019 earnings estimates have risen from $3.79 to $4.32 per share for 2024 while that for 2025 has increased from $7.24 to $7.38. GILD shares have risen 14.1% year to date. Gilead Sciences\u2019 earnings beat estimates in three of the trailing four quarters and missed the same in one, delivering an average surprise of 15.46%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Dr. Reddy's Laboratories Ltd (RDY) : Free Stock Analysis Report Pfizer Inc. (PFE) : Free Stock Analysis Report Gilead Sciences, Inc. (GILD) : Free Stock Analysis Report Coherus BioSciences, Inc. (CHRS) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CHRS", "date": "2024-11-29T18:09:00", "sentiment": {"score": 0.8159875455312431, "confidence": 0.8227454423904419, "probabilities": {"positive": 0.8227454423904419, "negative": 0.006757896859198809, "neutral": 0.1704966425895691}}, "embedding": [-0.04206608980894089, -0.06139145419001579, -0.1754106879234314, -0.2054101824760437, -0.08537383377552032, -0.03657089173793793, -0.15346962213516235, 0.16779884696006775, 0.07363017648458481, -0.0008643213659524918, -0.06058889627456665, 0.060219038277864456, 0.14298705756664276, 0.10654450953006744, 0.0273183174431324, 0.13136810064315796, -0.0053729587234556675, -0.06943799555301666, -0.009880568832159042, 0.06782814115285873, -0.04732659459114075, 0.011878926306962967, 0.13265280425548553, 0.04418070986866951, -0.047864846885204315, -0.16554337739944458, -0.08056668192148209, 0.009034816175699234, -0.08569877594709396, -0.04162506014108658, 0.11184367537498474, 0.15744641423225403, -0.13420292735099792, -0.13298600912094116, -0.01282469742000103, -0.039211589843034744, -0.12146539241075516, 0.08558496832847595, -0.08727870136499405, 0.0662103146314621, 0.08182570338249207, -0.04894031584262848, -0.13426384329795837, -0.032604873180389404, 0.025606617331504822, -0.18778282403945923, -0.14217519760131836, 0.027645234018564224, -0.048556696623563766, 0.1250322461128235, -0.14225637912750244, -0.10641010850667953, -0.04167696833610535, 0.08594506233930588, -0.04234832525253296, -0.1589072048664093, -0.10608838498592377, 0.014902251772582531, 0.02829880826175213, 0.05381760001182556, 0.0071251727640628815, -0.03030516766011715, 0.08953825384378433, 0.03366373851895332, 0.15381084382534027, -0.0191169586032629, 0.010795429348945618, -0.06860698759555817, 0.045295730233192444, -0.042347073554992676, 0.037220731377601624, -0.17980054020881653, -0.013786162249743938, 0.1411656141281128, -0.16839714348316193, -0.02250172197818756, 0.1922454684972763, 0.16671624779701233, 0.1516851782798767, -0.008313579484820366, 0.020064884796738625, 0.14807653427124023, 0.2355048954486847, -0.05055344104766846, -0.03541218489408493, 0.10315342247486115, -0.04507479444146156, 0.15434658527374268, -0.025206902995705605, -0.08849386870861053, 0.2851378917694092, 0.06229959428310394, -0.000521054957062006, 0.07150005549192429, -0.006697200238704681, -0.10932076722383499, 0.0645434707403183, 0.020786477252840996, 0.043189313262701035, -0.033961597830057144, 0.11126448214054108, -0.27588146924972534, -0.15461260080337524, -0.059464260935783386, -0.07743574678897858, -0.00047916825860738754, 0.05721673369407654, -0.07528256624937057, -0.004256654530763626, 0.04179508984088898, -0.11148452013731003, 0.12092602252960205, -0.012415963225066662, -0.002298358827829361, -0.12998872995376587, 0.19336839020252228, 0.01763962022960186, 0.037306323647499084, 0.19814789295196533, -0.09658248722553253, -0.035827748477458954, -0.09403225779533386, -0.023191016167402267, -0.16964545845985413, 0.14193934202194214, 0.08797523379325867, -0.17464014887809753, 1.0688015611590626e-32, 0.02914592996239662, 0.024546409025788307, 0.11214129626750946, -0.058998338878154755, -0.10949564725160599, 0.10847800225019455, 0.0856691300868988, 0.024550149217247963, -0.24269208312034607, -0.14224690198898315, -0.07468868046998978, 0.007968266494572163, 0.004747762344777584, 0.022319918498396873, -0.09574879705905914, -0.12850172817707062, -0.09426793456077576, -0.0010832631960511208, -0.07117576152086258, -0.09396317601203918, 0.058559272438287735, 0.09301269054412842, -0.023554138839244843, 0.16018742322921753, -0.06543286889791489, 0.07659413665533066, -0.07608946412801743, 0.0032012807205319405, 0.07577893882989883, 0.07799769937992096, -0.01518813893198967, -0.002005839254707098, -0.0720004290342331, -0.029366817325353622, -0.16530096530914307, -0.08544257283210754, -0.18667811155319214, -0.13384872674942017, -0.05224863439798355, 0.02740016207098961, 0.020712679252028465, 0.018559223040938377, -0.197272390127182, -0.08455479145050049, 0.052760183811187744, -0.07405446469783783, -0.18219077587127686, -0.001934892381541431, -0.06847352534532547, -0.061043668538331985, -0.14124557375907898, 0.003607343416661024, -0.13254797458648682, 0.0019036363810300827, 0.006265245843678713, 0.0350344255566597, -0.15356916189193726, -0.03484700620174408, 0.16133995354175568, 0.12450573593378067, 0.021137701347470284, -0.02065112069249153, 0.011077508330345154, 0.005603069439530373, 0.04366227984428406, 0.009013841859996319, 0.055511847138404846, -0.05989397317171097, -0.10691943764686584, 0.049305662512779236, 0.024750683456659317, -0.0351811908185482, 0.13203752040863037, 0.12558884918689728, 0.11553935706615448, -0.15937814116477966, 0.08804874122142792, 0.06886869668960571, 0.06798946112394333, 0.10797297954559326, 0.05686256289482117, 0.11230887472629547, -0.0003701746463775635, 0.06537039577960968, 0.02768474817276001, -0.14675195515155792, -0.08762900531291962, 0.002315760590136051, -0.11052251607179642, 0.09246658533811569, 0.11715780198574066, -0.07668699324131012, -0.02661970630288124, 0.0511464960873127, 0.04316392540931702, -1.0426881010923394e-32, -0.0036990176886320114, -0.005388622172176838, 0.03123563900589943, -0.01565505377948284, 0.06618940830230713, 0.09554153680801392, 0.10742196440696716, -0.11681243777275085, 0.09099748730659485, -0.07302150130271912, 0.08100762963294983, 0.08552098274230957, -0.013757402077317238, -0.04872078821063042, -0.021080248057842255, 0.05535247176885605, 0.041883476078510284, -0.06229081004858017, -0.1499749720096588, 0.08828982710838318, 0.018567079678177834, 0.026594750583171844, -0.12004406750202179, -0.03414292261004448, 0.009536510333418846, 0.01651955209672451, 0.06837882846593857, -0.013043999671936035, 0.14116770029067993, 0.030288320034742355, -0.03757025673985481, 0.06362470239400864, -0.3093179762363434, -0.022290842607617378, -0.03448209911584854, -0.11615702509880066, 0.020451992750167847, -0.17100577056407928, -0.04532197117805481, -0.046185269951820374, -0.037619367241859436, -0.015064038336277008, -0.05995885282754898, 0.0607806071639061, 0.04013797640800476, -0.01091389637440443, -0.05930355191230774, -0.01748361438512802, 0.12320303171873093, 0.08192717283964157, -0.04573885351419449, 0.09689430892467499, 0.09677695482969284, 0.019334441050887108, -0.00942655187100172, -0.11507542431354523, 0.04858319088816643, 0.01890261098742485, -0.09649553149938583, 0.03948374092578888, 0.09657437354326248, 0.05518178641796112, -0.10741201788187027, 0.01932152733206749, 0.060404933989048004, 0.24565687775611877, 0.07684268057346344, 0.02948644757270813, 0.12009485065937042, -0.13982707262039185, 0.0010048877447843552, 0.03225734084844589, -0.023531842976808548, -0.13264891505241394, -0.0017543209251016378, 0.2088586539030075, -0.020440924912691116, -0.1409972459077835, -0.08032428473234177, -0.030857592821121216, 0.015026800334453583, -0.007894828915596008, 0.08728636056184769, -0.03061758726835251, 0.10282862186431885, 0.05001933500170708, 0.05183887481689453, -0.018908223137259483, 0.022590482607483864, 0.001571584027260542, -0.019112784415483475, -0.16902460157871246, -0.09912283718585968, 0.1607644259929657, 0.09129495173692703, -1.0080036361159728e-07, 0.06301023066043854, -0.21451833844184875, -0.018691111356019974, -0.12141246348619461, -0.0026145223528146744, 0.023132547736167908, -0.004859353415668011, 0.04696468263864517, -0.005729293450713158, 0.22871051728725433, 0.10112182796001434, 0.14698438346385956, -0.005127663258463144, -0.01872633770108223, -0.009805068373680115, 0.00965508259832859, 0.13649962842464447, 0.0875968337059021, -0.020133011043071747, 0.02780836448073387, -0.0706491470336914, 0.032687678933143616, -0.02507850155234337, -0.004112124443054199, 0.09158766269683838, 0.006050173193216324, -0.029799453914165497, 0.07406771183013916, 0.09642685949802399, -0.09762255847454071, -0.009909039363265038, -0.028954464942216873, 0.12319270521402359, -0.01858130842447281, -0.07432452589273453, -0.057090532034635544, 0.0907142162322998, 0.08218999207019806, 0.07995802164077759, 0.03154247626662254, 0.12265443801879883, -0.012563725002110004, -0.002723463112488389, -0.011469163000583649, -0.02838437259197235, 0.004377629607915878, -0.15580183267593384, -0.0407690703868866, -0.017010044306516647, -0.08230110257863998, -0.04556123912334442, -0.07059988379478455, 0.03625926747918129, -0.08805099129676819, -0.07395326346158981, 0.20332249999046326, -0.042923588305711746, -0.09413939714431763, 0.1104205846786499, -0.04992014169692993, 0.058305524289608, -0.1486666053533554, 0.23864443600177765, 0.024152811616659164], "changes": {"1wk": 39.34426293581987, "1mo": 22.131145458585426}}]